INDEX TO VOLUME 16

(S = supplement; L = letter to the Editors; P = proceedings)

AUTHOR INDEX

AARBAKKE, J. *see* BREIBY, M.

AARONS, L. *see* GRENNAN, D.M.

ABILA, B., MARSHALL, R.W., WILSON, J.F. & RICHENS, A. Do β-adrenoceptor blockers have a peripheral or central effect in essential tremor? 210P

ACIOLI, A. *see* COSTA E SILVA, J.A.

ADAM, K. *see* MONTGOMERY, I.

ADAMS, P.C. *see* GIBB, I.

ADEYOKUNNU, A.A. *see* WALKER, O.

ADIE, C.J. *see* WATHEN, C.G.

ADVENIER, C., ROUX, A., GOBERT, C., MASSIAS, P., VAROQUAUX, O. & FLOUVAT, B. Pharmacokinetics of ketoprofen in the elderly, 65

AGNEW, E. *see* RAPEPORT, W.G.

AGUGLIA, U. *see* QUATTRONE, A.

AHERNE, G.W. *see* SLEVIN, M.L.

AHMAD, F., RITTMEYER, P., GOETZKE, E. & KÖSTER, J. Brotizolam as a pre-operative hypnotic, 419S

AL-HILLI, S. *see* CHANNER, K.S.

ALTAMURA, A.C. & MELORIO, T. Mianserin metabolites, 201L

ALTERWAIN, P. *see* MONTI, J.M.

ALVAN, G. *see* WALKER, O.

AMERY, A. *see* STAESSEN, J.

AMREIN, R., ECKERT, M., HAEFELI, H. & LEISHMAN, B. Pharmacokinetic and clinical considerations in the choice of a hypnotic, 5S

ANDREASEN, F., HUSTED, S., HANSEN, U. & JANSEN, J. The pharmacokinetics of frusemide are influenced by age, 207P

ANDREASEN, F., HANSEN, U., HUSTED, S.E. & JANSEN, J.A. The pharmacokinetics of frusemide are influenced by age, 391

ANKIER, S.I., BARCLAY, S.P. & WARRINGTON, S.J. Loprazolam (RU31158)—lack of effect on hepatic microsomal enzyme activity in man, 201L

ANKIER, S.I. *see* BAYER, A.J.

ANKIER, S.I. *see* MCMANUS, I.C.

ANNUNZIATO, L. *see* QUATTRONE, A.

ARIAS-ORTIZ, J.L. *see* FRITZ-OSNER, A.

ARMITSTEAD, J.G., LIGHTMAN, S.L., BROWN, M.J., CAUSON, R.C. & VAUGHAN, N.J.A. The effect of selective and non-selective β-adrenoceptor blockade, and of naloxone infusion, on the hormonal mechanisms of recovery from insulin-induced hypoglycaemia in man, 718

ARMSTRONG, P.W., WATTS, D.G. & MOFFATT, J.A. Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure, 385

ARNDTS, D. *see* HARRON, D.W.G.

ARNOLD, J.M.O. & MCDEVITT, D.G. An assessment of physiological finger tremor as an indicator of β-adrenoceptor function, 167

ARNOLD, J.M.O. & MCDEVITT, D.G. Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine, 175

ARNOLD, J.M.O. *see* O'CONNOR, P.C.

ASTHANA, O.P., WOODCOCK, B.G. & RIETBROCK, N. PQ intervals and absorption following sublingual, buccal and oral administration of verapamil, 206P

ATTWOOD, J. *see* MINERS, J.O.

AVIRAM, M. *see* MARKEL, A.

BAARS, L.G. *see* THIJSSEN, H.H.W.

BACK, D.J., BRECKENRIDGE, A.M., ORME, M.C.L'E. & SHAW, M.A. Urinary steroid glucuronides in women taking oral contraceptives, 227P

BACK, D.J., PARK, B.K., TJIA, J.F. & NEWBY, J.N. Sulphaphenazole and drug oxidation in man, 460L

BACK, D.J., PURBA, H.S., PARK, B.K., WARD, S.A. & ORME, M.L'E. Effect of chloroquine and primaquine on antipyrine metabolism, 497

BAI, S.A. *see* HURWITZ, G.A.

BAKKE, O.M. *see* LIEN, E.

BALL, S.G. *see* ZOCCALI, C.

BALLMER, U. *see* LUPOLOVER, R.

BANFIELD, C., O'REILLY, R., CHAN, E. & ROWLAND, M. Phenylbutazone—warfarin interaction in man: further stereochemical and metabolic considerations, 669

BARBIERI, C. *see* CALDARA, R.

BARCLAY, S.P. *see* ANKIER, S.I.

BARNES, J.N. *see* VANDENBURG, M.J.

BAR-ON, E. *see* GATH, I.

BARR, R.M., MISCH, K.J., HENSBY, C.N., MALLET A.I. & GREAVES, M.W. Arachidonic acid and prostaglandin levels in dithranol erythema: time course study, 715

BARRADAS, M.A., MIKHAILIDIS, D.P. & DANDONA, P. The effect of fenfluramine on collagen-induced platelet aggregation *in vitro*, 459L

BARTON, N.K. *see* SLEVIN, M.L.

BASHIR, A. *see* CULLING, W.

BATEMAN, D.N., CHAPMAN, P.H. & RAWLINS, M.D. The acute and chronic effects of H_1-receptor blockade with astemizole on indocyanine green clearance, 241

BATEMAN, D.N. & RAWLINS, M.D. The effects of astemizole on antipyrine clearance, 759L

BATEMAN, D.N. *see* TAYLOR, W.B.

BAYER, A.J., PATHY, M.S.J. & ANKIER, S.I. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly, 371

BEAUNE, P.H. *see* CRESTEIL, T.

BECHTEL, W.D. Pharmacokinetics and metabolism of brotizolam in animals, 261S
BECHTEL, W.D. Pharmacokinetics and metabolism of brotizolam in humans, 279S
BECHTEL, W.D. *see* EVERS, J.
BECHTOLD, H., TRENK, D., MEINERTZ, T., ROWLAND, M. & JÄHNCHEN, E. Cyclic interconversion of vitamin K_1 and vitamin K_1 2,3,-epoxide in man, 683
BECK, H., SALOM, M. & HOLZER, J. Midazolam dosage studies in institutionalized geriatric patients, 133S
BELL, A.J. *see* EDMONDSTONE, W.M.
BELL, G.D., RICHMOND, C.R. & SOMERVILLE, K.W. Peppermint oil capsules (Colpermin) for the irritable bowel syndrome: a pharmacokinetic study, 228P
BELL, G.D., RICHMOND C.R., ROTHWELL, K. & WHITTEN, B. Effect of ibuprofen on the concentration of mucus glycoprotein in human bile, 229P
BELL, R.M. *see* BENEDEK, I.H.
BELLAMY, G.R., HUNYOR, S.N., ROFFE D. & MASSANG, J. Magnitude and mechanisms of the antihypertensive action of pabetalol, including ambulatory assessment, 9
BENEDEK, I.H., FISKE, W.D., GRIFFEN, W.O., BELL, R.M.,BLOUIN, R.A. & MCNAMARA, P.J. Serum α_1-acid glycoprotein and the binding of drugs in obesity, 751
BENNETT, P.N., NOTARIANNI, L.J., PATEL, D.K. & HO, S.G. Evidence for glycine depletion after aspirin overdose, 219P
BENNETT, T. *see* WILCOX, R.G.
BENTAL, E. *see* GATH, I.
BERGLUND, G. *see* HEDNER, T.
BERGUSSON, P. *see* PREISS, D.
BERNARD, R. *see* RENARD, M.
BIRKETT, D.J. *see* MINERS, J.O.
BJORNSSON, T.D. *see* MCGOWAN, F.X.
BLOUIN, B.A. *see* BENEDEK, I.H.
BÖKE-KUHN, K. *see* KUHN, F.J.
BOLTON, J.E. *see* GILCHRIST, N.
BOLTON, R. *see* CHANNER, K.S.
BONDESEN, S. *see* HAAGEN NIELSEN, O.
BOOBIS, A.R., HAMPDEN, C., MURRAY, S. & DAVIES, D.S. Reciprocal inhibition of debrisoquine and bufuralol oxidation in man, 218P
BORNSTEIN, S. *see* UZZAN, B.
BORODA, C. *see* MAHAJAN, P.
BOYD LOADHOLT, C. *see* HURWITZ, G.A.
BRACHET-LIERMAIN, A. *see* CENRAUD, B.
BRADBROOK, I.D. *see* WOOLF, A.D.
BRECKENRIDGE, A.M. *see* BACK, D.J.
BREDESEN, J.E. *see* PIKE, E.
BREIBY, M., AARBAKKE, J., SUNDSFJORD, J., GOUSSIUS, G. & PAPE, J. Effect of posture on ampicillin pharmacokinetics, glomerular filtration rate and renal plasma flow in resting subjects, 691
BREIMER, D.D. & JOCHEMSEN, R. Clinical pharmacology of hypnotic benzodiazepines: a summary, 277S
BREIMER, D.D. *see* JOCHEMSEN, R.
BRODIE, M.J., FORREST, G. & RAPEPORT, W.G. Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants, 747
BRODIE, M.J. *see* RAPEPORT, W.G.
BRODTHAGEN, U. *see* JÜRGENSEN, H.J.
BROOK, J.G. *see* MARKEL, A.
BROOKS, P.M. *see* MEFFIN, P.J.
BROUSTET, J.P. *see* HILAIRE, J.
BROWN, A.N. *see* FRANCIS, R.J.
BROWN, M.J. *see* ARMITSTEAD, J.G.
BROWN, R.A. *see* POTTS, R.C.
BROWN, S. *see* DIFFEY, B.L.
BRUNNER, F. *see* HOUIN, G.
BRYSON, S.M, VERMA, N., SCOTT, P.J.W. & RUBIN, P.C. Pharmacokinetics of valproic acid in young and elderly subjects, 104
BUNCH, C. *see* WHITE, N.J.
BURROUGHS, A.K. *see* DUNK, A.A.
BURY, R.W. *see* CHING, M.S.
BUTTERS, L. *see* RUBIN, P.C.

CALDARA, R., MASCI, E., BARBIERI, C., CAMBIELLI, M., FERRARI, C. & TITTOBELLO, A. Dopaminergic control of gastric acid and gastrin secretion in man: lack of effects after acute oral administration of ibopamine, an analogue of dopamine, 112
CALVERT, A.H. *see* NEWELL, D.R.
CALVEY, T.N. *see* MILNE, L.A.
CAMBIELLI, M. *see* CALDARA, R.
CAPELLÀ, D. *see* LAPORTE, J.-R.
CASANOVA, P. *see* GALLAIS, H.
CASTLE, W.M., NICHOLLS, J.T. & DOWNIE, C.C. Problems of post-marketing surveillance, 581
CASTELDEN, C.M. *see* DEY, N.G.
CATTAERT, A. *see* STAESSEN, J.
CAUSON, R.C. *see* ARMITSTEAD, J.G.
CÉLIER, C. *see* CRESTEIL, T.
CENRAUD, B., GUYOT, M., LEVY, R.H., BRACHET-LIERMAN A., MORSELLI, P.L., MORELAND, T.A. & LOISEAU, P. No effect of food intake on clobazam absorption, 728
CHADA, D.R. & HOUTZAGERS, J.J.R. A comparison of a combination of penbutolol and frusemide with the two compounds individually in the treatment of hypertension, 561
CHAN, E. *see* BANFIELD, C.
CHAN, K. *see* MILNE L.A.
CHANNER, K.S., BOLTON, R., AL-HILLI, S., NAKIELNY, R. & VIRJEE, J.P. The effect of glucagon on the swallowing of capsules, 456
CHANTHAVANICH, P. *see* WHITE, N.J.
CHIANG, B.N. *see* HONG, C.Y.
CHAPMAN, P.H. *see* BATEMAN, D.N.
CHARLES, B.G. *see* MOSES, D.K.
CHERFAOUI, M. *see* HOUIN, G.
CHERMAT, P. *see* UZZAN, B.
CHESTNUTT, W.N. *see* ELWOOD, R.J.
CHING, M.S., RAYMOND K., BURY, R.W., MASHFORD, M.L. & MORGAN, D.J. Absorption of orally administered amphotericin B lozenges, 106
CLARK, T.J.H. *see* WARREN, J.B.
CLARKE, R.S.J. *see* FERRES, C.J.
CLEE, M. *see* FEELY, J.
CLEMENTS, J.A. *see* MITCHELL, B.G.
CLUR, B.K. *see* MEYER, B.H.
COCHRAN, M. *see* MEFFIN, P.J.
COCHRANE, G.M. *see* WARREN, J.B.
COHN, M.A. Hypnotics and the control of breathing, 245S
COOK, P.J., MAIDMENT, C.G., DANDONA, P., HUTTON, R.A. & JAMES, I.M. The effect of intravenous epopros-

tenol (prostacyclin, PGI_2) on cerebral blood flow and cardiac output in man, 707
COLLE, J.P. *see* HILAIRE, J.
COLLIER, J.G. & FULLER, R.W. Evidence for an effect of sodium cromoglycate on sensory nerves in man, 639
COLUSSI, D., SCHOELLER, J.P., RICHARD, A. & SIOUFI, A. Pharmacokinetics of chlorthalidone in the elderly after single and multiple doses, 755L
COOMBS, R.R.A., CUTHBERT, A.W. & MCLAUGHLAN, P. Reactions to milk proteins in colonic epithelia from milk-fed guinea-pigs, 213P
COOPER, M. *see* DEVONSHIRE, H.W.
COOPER, M.J. & WILLIAMSON, R.C.N. The action of salicylates on bile flow in man, 570
CORFARIU, O. *see* POPOVICIU, L.
CORLESS, D. *see* JOCHEMSEN, R.
CORLESS, D. *see* WOOLF, A.D.
CORNHILL, J. *see* DEY, N.G.
COSTA E SILVA, J.A., ACIOLI, A., NAYLOR, C., JONES DA SILVA, C. & FERREIRA, I. Midazolam and triazolam in out-patients: a double-blind comparison of hypnotic efficacy, 179S
CRAGG, D.J.B. *see* TATTERSFIELD, A.E.
CREAGH, F.M. *see* GRIFFITHS, B.E.
CRESTEIL, T., CÉLIER, C., KREMERS, P., FLINOIS, J.P., BEAUNE, PH. & LEROUX, L.P. Induction of drug-metabolizing enzymes by tricyclic antidepressants in human liver: characterization and partial resolution of cytochrome P-450, 651
CREVOISIER, CH., ZIEGLER, W.H., ECKERT, M. & HEIZMANN, P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration, 51S
CROOKS, J. *1982 Lilly Prize Lecture.* Drug epidemiology and clinical pharmacology: their contribution to patient care, 351
CROOKS, J. *see* SWIFT, C.G.
CSIMA, A. *see* MAMELAK, M.
CULLING, W., SINGH, H., BASHIR, A., GRIFFITHS, B.E., DALAL, J.J. & SHERIDAN, D.J. Acute pharmacokinetics and haemodynamic effects of inhaled isosorbide dinitrate and sublingual GTN, 204P
CUTHBERT, A.W. *see* COOMBS, R.R.A.

DALAL, J.J. *see* CULLING, W.
DALTON, N. *see* WARREN, J.B.
DAMMANN, H.G., FRIEDL, W., MÜLLER, P. & SIMON, B. Effect of ranitidine and cimetidine twice daily on the 24 h intragastric acidity in man, 461L
DANDONA, P. *see* BARRADAS, M.A.
DANDONA, P. *see* COOK, P.J.
DANESHMEND, T.K., WARNOCK, D.W., ENE, M.D., JOHNSON E.M., PARKER, G., RICHARDSON, M.D. & ROBERTS, C.J.C. The effects of ketoconazole on antipyrine kinetics in man, 225P
D'ANGELO, L. *see* MONTI, J.M.
DANIEL, H.B. *see* HURWITZ, G.A.
DANNEBERG, P. & WEBER, K.H. Chemical structure and biological activity of the diazepines, 231S
DANNEBERG, P. *see* KUHN, F.J.
DANTZO, B. *see* UZZAN, B.
DAVIES, D.S. *see* BOOBIS, A.R.
DAWODU, A.H. *see* WALKER, O.
DAWSON, S. *see* THOMPSON, P.J.
DEBELLIS, J. *see* MONTI, J.M.
DENISON, D.M. *see* EDMONDSTONE, W.M.
DE SCHAEPDRYVER, A. *see* STAESSEN, J.
DEVONSHIRE, H.W., KONG, I., COOPER, M., SLOAN, T.P., IDLE, J.R. & SMITH, R.L. The contribution of genetically determined oxidation status to inter-individual variations in phenacetin disposition, 157
DEW, M.J., RYDER, R.E.J., EVANS, N., EVANS, B.K. & RHODES, J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis, 185
DEY, N.G., CASTLEDEN, C.M., WARD, J., CORNHILL, J. & MCBURNEY, A. The effect of cimetidine on tolbutamide kinetics, 438
DICK, R. *see* DUNK, A.A.
DIFFEY, B.L. & BROWN, S. A method for predicting the phototoxicity of non-steroidal anti-inflammatory drugs, 633
DIRENZO, G.F. *see* QUATTRONE, A.
DOBBS, R.J. *see* ROBINSON, B.F.
DOLLERY, C.T. *see* HEAVEY, D.J.
DONALD, R.A. *see* GILCHRIST, N.
DORANTES, J.F. *see* FRITZ-OSNER, A.
DOWNIE, C.C. *see* CASTLE, W.M.
DRESSE, A. *see* RENARD, M.
DREW, P.J. *see* VANDENBURG, M.J.
DU CAILAR, J., HOLZER, J., JULLIEN, Y. & PASSERON, D. Hypnotic efficacy of midazolam in pre-surgical patients: a dose-finding study, 129S
DUFFIN, D. *see* TAYLOR, D.R.
DUNDEE, J.W. *see* ELWOOD, R.J.
DUNK, A.A., JENKINS, W.J., BURROUGHS, A.K., WALT, R.P., OSUAFOR, T.O.K., SHERLOCK, S., MACKIE, S. & DICK, R. The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease, 117
DÜSING, R., NICOLAS, V., GLATTE, B., GLÄNZER K., KIPNOWSKI, J. & KRAMER, H.J. Interaction of bemetizide and indomethacin in the kidney, 377

ECKERT, M. *see* AMREIN, R.
ECKERT, M. *see* CREVOISIER, Ch.
ECKERT, M. *see* HEIZMANN, P.
ECKERT, M. *see* ZIEGLER, W.H.
EDMONDSTONE, W.M., WALLER, J.F., MANGHANI, K.K., HILL, P.L., BELL, A.J. & DENISON, D.M. Pulmonary effects in man of oral prizidilol hydrochloride (SK&F 92657), a new antihypertensive agent, 591
EHSANULLAH, R.S.B. *see* JACKSON, S.H.D.
ELDOR, A. *see* LEVY, M.
ELIAKIM, M. *see* LEVY, M.
ELLIOT, H.L. *see* MEREDITH, P.A.
ELLIOTT, P. *see* ELWOOD, R.J.
ELLUL-MICALLEF, R. The effect of terbutaline sulphate in chronic 'allergic' cough, 224P
ELWES, R.D.C. *see* SHORVON, S.D.
ELWOOD, R.J., ELLIOTT, P., CHESTNUTT, W.N., HILDEBRAND, P.J. & DUNDEE, J.W. A comparison of the onset and duration of action of zopiclone with diazepam, 216P
ENE, M.D. *see* DANESHMEND, T.K.
ERICSSON, F. *see* JOGESTRAND, T.
ESCHER, J. *see* LUPOLOVER, R.
ETIENNE, J., MILLOT, F., PIERON, R. & LARUELLE, P.

Release of LPL activity after intravenous injection of a low molecular weight heparin, 712
EVANS, B.K. *see* DEW, M.J.
EVANS, J. *see* RUBIN, P.C.
EVANS, N. *see* DEW, M.J.
EVERS, J., RENNER, E. & BECHTEL, W.D. Pharmacokinetics of brotizolam in renal failure, 309S

FABREGAT, H. *see* GALLAIS, H.
FAGARD, R. *see* STAESSEN, J.
FALCONER, A.D. & WATERLAND, J. The influence of pregnancy on maternal vascular responses to ritodrine hydrochloride, 209P
FEELY, J., CLEE, M., PEREIRA, L. & GUY, E. Enzyme induction with rifampicin: lipoproteins and drug binding to α_1-acid glycoprotein, 19S
FELDMEIER, Ch. & KAPP, W. Comparative clinical studies with midazolam, oxazepam and placebo, 151S
FERRARI, C. *see* CALDARA, R.
FERREIRA, I. *see* COSTA E. SILVA, J.A.
FERRES, C.J., MIRAKHUR, R.K., CLARKE, R.S.J. & PANDIT, S.K. Neuromuscular blocking effects of a combination of vecuronium and pancuronium, 218P
FILE, S.E. & LISTER, R.G. Does tolerance to lorazepam develop with once weekly dosing, 645
FINCH, M.B., KELLY, J.G., JOHNSTON, G.D. & MCDEVITT, D.G. Evidence against a digoxin—indomethacin interaction, 212P
FINCH, M.B. *see* FRANCIS, R.J.
FINCH, M.B. *see* HARRON, D.W.G.
FINCH, M.B. *see* O'CONNOR P.C.
FINDEISEN, P. *see* GOETZKE, E.
FINDEISEN, P. *see* LOHMANN, H.
FISCHBACH, R. Hypnotic efficacy and safety of midazolam and oxazepam in hospitalized female patients, 157S
FISCHBACH, R. Efficacy and safety of midazolam and Vesparax in treatment of sleep disorders, 167S
FISKE, W.D. *see* BENEDEK, I.H.
FLINOIS, J.P. *see* CRESTEIL, T.
FLOUVAT, B. *see* ADVENIER, C.
FORREST, G. *see* BRODIE, M.J.
FORREST, G. *see* RAPEPORT, W.G.
FRANCIS, R.J., BROWN A.N., GALLOWAY D.B., O'CONNOR, P.C., FINCH, M.B., HARRON, D.W.G., MCDEVITT, D.G. & SHANKS, R.G. Pharmacokinetics of Ro 31-1118, a new cardioselective β-adrenoceptor antagonist, 210P
FRANCIS, R.J. *see* O'CONNOR, P.C.
FRANKLIN, R.A. *see* PIERCE, D.M.
FRASER, R. *see* ZOCCALI, C.
FREESTONE, S. *see* RAMSAY, L.E.
FRENCH, G. *see* RAPEPORT, W.G.
FRIEDL, W. *see* DAMMANN, H.G.
FRITZ-OSNER, A. ARIAS-ORTIZ, J.L., DORANTES, J.F., RABAGO-SÁNCHEZ, J., RODRÍGUEZ-TENORIO, A. & SÁNCHEZ-MARTINEZ, J. Brotizolam and chronic insomnia: a multi-centre study, 413S
FULLER, R.W. *see* COLLIER, J.G.

GAFFNEY, T.E. *see* HURWITZ, G.A.
GAILLARD, J.-M. Biochemical pharmacology of paradoxical sleep, 205S
GALLAIS, H., CASANOVA P. & FABREGAT, H. Midazolam and oxazepam in the treatment of insomnia in hospitalized patients, 145S
GALLOWAY, D. *see* FRANCIS, R.J.
GALLOWAY, D. *see* O'CONNOR, P.C.
GARDNER, M.J., TORNATORE, K.M., JUSKO, W.J. & KANARKOWSKI, R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition, 271
GATH, I., BAR-ON, E., ROGOWSKI, Z. & BENTAL, E. Automatic scoring of polygraphic sleep recordings: Midazolam in insomniacs, 89S
GEMPERLE, M. & KAPP, W. Midazolam and anaesthesia, 187S
GEORGE, C.F. *see* RENWICK, A.G.
GEORGE, C.F. *see* SMITH, R.S.
GERECKE, M. Chemical structure and properties of midazolam compared with other benzodiazepines, 11S
GIBB, I., ADAMS, P.C., PARNHAM, A.J. & JENNINGS, K. Plasma digoxin: assay anomalies in Fab-treated patients, 445
GIBBS, J.H. *see* POTTS, R.C.
GILCHRIST, N., BOLTON, J.E., DONALD, R.A., LIVESEY, J.H., ROUD, H.K. & NICHOLLS, M.G. Hormonal effects and metabolic clearance rate of the enkephalin analogue DAMME in man, 465
GLATTE, B. *see* DÜSING, R.
GLÄNZER, K. *see* DÜSING, R.
GLEESON, D., ROSE, J.D.R. & SMITH, P.M. A prospective randomised controlled trial of diazepam (Valium) *vs* emulsified diazepam (Diazemuls) as a premedication for upper gastrointestinal endoscopy, 448
GOBERT, C. *see* ADVENIER, C.
GOETZKE, E., FINDEISEN, P. & WELBERS, I.B. Tolerance and efficacy: comparative studies with brotizolam and flunitrazepam, 397S
GOETZKE, E., FINDEISEN, P. & WELBERS, I.B. Comparative study on the efficacy of and the tolerance to the triazolodiazepines, triazolam and brotizolam, 407S
GOETZKE, E. *see* AHMAD, F.
GOETZKE, E. *see* VON DELBRÜCK, O.
GOOPTU, D. *see* ZAR, M.A.
GOURLEY, L. *see* HURWITZ, G.A.
GOUSSINS, G. *see* BREIBY, M.
GRAINGER, S.L. & SMITH, S.E. Dose-response relationships of intravenous hyoscine butylbromide and atropine sulphate on heart rate in healthy volunteers, 623
GRAY, J.D., RENTON, K.W. & HUNG, O.R. Depression of theophylline elimination following BCG vaccination, 735
GREAVES, M.W. *see* BARR, R.M.
GREENBLATT, D.J. *see* OCHS, H.R.
GRENNAN, D.M., AARONS, L., SIDDIQUI, M., RICHARDS, M., THOMPSON, R. & HIGHAM, C. Pharmacokinetic studies with ibuprofen in rheumatoid arthritis, 214P
GRGURINOVICH, N. *see* MEFFIN, P.J.
GRIFFEN, W.O. *see* BENEDEK, I.H.
GRIFFITHS, B.E., CREAGH, F.M., LAZARUS, J.H., JOHN, R. & KADURY, S. Effect of timolol on clinical features and echocardiographic assessment of left ventricular function in hyperthyroidism, 609
GRIFFITHS, B.E. *see* CULLING, W.
GRIGOLEIT, H.-G. *see* MEYER, B.H.
GRÜNEBERGER, J. *see* SALETU, B.
GUDGEON, A.C. & HINDMARCH, I. Midazolam: Effects on psychomotor performance and subjective aspects of sleep and sedation in normal volunteers, 121S
GUNNARSSON, P.O. *see* PLYM FORSHELL, G.

GUY, E. *see* FEELY, J.
GUYOT, M. *see* CENRAUD, B.

HAAGEN NIELSEN, O. & BONDESEN, S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man, 738
HAEFELI, H. *see* AMREIN, R.
HAMLEY, J. *see* SWIFT, C.G.
HAMPDEN, C. *see* BOOBIS, A.R.
HANNAN, W.J. *see* WATHEN, C.G.
HANSEN, U. *see* ANDREASEN, F.
HARRAP, K.R. *see* NEWELL, D.R.
HARRON, D.W.G., ARNDTS, D., FINCH, M. & SHANKS, R.G. An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine, 451
HARRON, D.W.G. *see* FRANCIS, R.J.
HARRON, D.W.G. *see* O'CONNOR, P.C.
HARTSE, K.M., THORNBY, J.I., KARACAN, I. & WILLIAMS, R.L. Effects of brotizolam, flurazepam and placebo upon nocturnal auditory arousal thresholds, 355S
HARVEY, V.J. *see* SLEVIN, M.L.
HASSAIN, H.A.A. *see* POTTS, R.C.
HAURI, P., ROTH, T., SATEIA, M. & ZORICK, F. Sleep laboratory and performance evaluation of midazolam in insomniacs, 109S
HAWKSWORTH, G.M. *see* SCOTT, A.K.
HAYLER, A.M. *see* HOLT, D.W.
HEALEY, G.F. *see* HOLT, D.W.
HEAVEY, D.J., IND, P.W., MIYATAKE, A. & DOLLERY, C.T. Local histamine release following intradermal antigen challenge, 214P
HEDGES, A. *see* SOWEMIMO-COKER, S.O.
HEDNER, T., PERSSON, B. & BERGLUND, G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension, 121
HEIDEMANN, H. *see* KIRCH, W.
HEIZMANN, P., ECKERT, M. & ZIEGLER, W.H. Pharmacokinetics and bioavailability of midazolam in man, 43S
HEIZMANN, P. *see* CREVOISIER, Ch.
HELCL, J. *see* LUPOLOVER, R.
HELENGLASS, G. *see* McINNES, G.T.
HENDERSON, A.H. *see* SINGH, H.
HENDRIKS, F.F.A. & SCHIPPERHEYN, J.J. Transients in oxygen uptake after step-increase of workload under β-adrenoceptor blockade or vasodilation, 319
HENSBY, C.N. *see* BARR, R.M.
HERMAN, R.J., NAKAMURA, K., WILKINSON, G.R. & WOOD, A.J.J. Induction of propranolol metabolism by rifampicin, 565
HERMANS, J. *see* JOCHEMSEN R.
HEWETT, C., KREUZER, H., KÖLLMER, H., NIGGESCHULZE, A. & STÖTZER, H. Toxicology of brotizolam, 267S
HIGGINS, V. *see* RENWICK, A.G.
HIGHAM, C. *see* GRENNAN, D.M.
HILDEBRAND, P.J. *see* ELWOOD, R.J.
HILL, P.L. *see* EDMONDSTONE, W.M.
HILLAIRE, J., BRONSTET, J.P., COLLE, J.P. & THERON, M. Cardiovascular effects of AQ-A 39 in healthy volunteers, 627
HILTON, S.A. *see* McEWEN, J.
HINDMARCH, I. *see* GUDGEON, A.C.
HO, S.G. *see* BENNETT, P.N.
HOFFMANN, J.J.M.L., THIEN, TH. & VAN 'T LAAR, A. Effects of intravenous endralazine in essential hypertension, 39
HOLDER, R. *see* ROLF SMITH, S.
HOLT, D.W., STOREY, G.C.A., JACKSON, P.R., TUCKER, G.T. & MCKENNA, W.J. Amiodarone pharmacokinetics, 206P
HOLT, D.W., HAYLER, A.M. & HEALEY, G.F. Effect of age and plasma concentrations of albumin and α_1-acid glycoprotein on protein binding of disopyramide, 344L
HOLT, J.E., SANKEY, M.G. & KAYE, C.M. Simple high-performance liquid chromatographic assay method for monitoring hydrochlorothiazide levels in plasma, 222P
HOLZER, J. *see* BECK, H.
HOLZER, J. *see* DU CAILER, J.
HONG, C.Y., CHIANG, B.N. & WEI, Y.H. Mitochondrial respiration inhibitors and human sperm motility: implication in the development of spermicides, 487
HOUIN, G., BRUNNER, F., NEBOUT, TH., CHERFAOUI, M., LAGRUE, G. & TILLEMENT, J.P. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man, 245
HOUTZAGERS, J.J.R. *see* CHADHA, D.R.
HUGENHOLTZ, P.G. *see* SERRUYS, P.W.
HUNG, O.R. *see* GRAY, J.D.
HUNYOR, S.N. *see* BELLAMY, G.R.
HURWITZ, G.A., WEBB, J.G., WALLE, T., BAI, S.A., DANIELL, H.B., GOURLEY, L., BOYD LOADHOLT, C. & GAFFNEY, T.E. Exercise-induced increments in plasma levels of propranolol and noradrenaline, 599
HUSSAIN, M. *see* SILKE, B.
HUSTED, S. *see* ANDREASEN, F.
HUTTON, R.A. *see* COOK, P.J.
HUYSMANS, F.TH. M., SLUITTER, H.E., THIEN, TH. A. & KOENE, R.A.P. Acute treatment of hypertensive crisis with nifedipine, 725

IBRAHEEM, J.J., PAALZOW, L. & TFELT-HANSEN, P. Low bioavailability of ergotamine tartrate after oral and renal administration in migraine sufferers, 695
IDLE, J.R. *see* DEVONSHIRE, H.W.
ILIOPOULOU, A., LEVIS, G. & MOULOPOULOUS, S. Diprophylline in biological fluids by high performance liquid chromatography, 223P
INANAGA, K. *see* TANAKA, M.
IND, P.W. *see* HEAVEY, D.J.
INGLIS, G.C. *see* ZOCCALI C.
ISHIZAKI, T., OYAMA, Y., SUGANUMA T., SASAKI, T., NAKAYA, H., SHIBUYA, T. & SATO, T. A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, β-adrenoceptor blockade and steady-state pharmacokinetics, 17
ISLES, C.G. *see* ZOCCALI, C.
ISOZAKI, H. *see* TANAKA, M.

JACK, D.B., WILKINS, M. & QUARTERMAN, C.P. Lack of evidence for polymorphism in metoprolol metabolism, 188
JACKSON, P.R. *see* HOLT, D.W.
JACKSON, S.H.D., TURNER, P. & EHSANULLAH, R.S.B. A comparison of diclofensine and desmethylimipramine using tyramine pressor tests in normal subjects, 427
JACOBS, PH. *see* RENARD, M.
JÄHNCHEN, E. *see* BECHTOLD, H.
JAMES, I.M. *see* COOK, P.J.

JANSEN, J.A. *see* ANDREASEN, F.
JENKINS, W.J. *see* DUNK, A.A.
JENNER, P., PRATT, J., REYNOLDS, E.H. & SHORVON, S.D. Different effects of anticonvulsant drugs on plasma tryptophan levels in epileptic patients, 215P
JENNINGS, K. *see* GIBB, I.
JOCHEMSEN, R., WESSELMAN, J.G.J., HERMANS, J., van BOXTEL, C.J. & BREIMER, D.D. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration, 285S
JOCHEMSEN, R., WESSELMAN, J.G.J., van BOXTEL, C.J., HERMANS, J. & BREIMER, D.D. Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects, 291S
JOCHEMSEN, R., NANDI, K.L., CORLESS, D., WESSELMAN, J.G.J. & BREIMER, D.D. Pharmacokinetics of brotizolam in the elderly, 299S
JOCHEMSEN, R., JOERES, R.P., WESSELMAN, J.G.J., RICHTER, E. & BREIMER, D.D. Pharmacokinetics of oral brotizolam in patients with liver cirrhosis, 315S
JOCHEMSEN, R. *see* BREIMER, D.D.
JOERES, R.P. *see* JOCHEMSEN, R.
JOGESTRAND, T. & ERICSSON, F. Skeletal muscle digoxin binding in patients with renal failure, 109
JOHN, R. *see* GRIFFITHS, B.E.
JOHNSON, A.L. *see* SHORVON S.D.
JOHNSON, E.M. *see* DANESHMEND, T.K.
JOHNSTON, A. *see* SLEVIN, M.L.
JOHNSTON, G.D. *see* FINCH, M.B.
JONES DA SILVA, C. *see* COSTA E SILVA, J.A.
JULLIEN, Y. *see* DU CAILAR, J.
JUMA, F. & OGADA, T. Pharmacokinetics of cyclophosphamide in Kenyan Africans, 61
JÜRGENSEN, H.J., WIMBERLEY, P.D. & BRODTHAGEN, U. Oxyhaemoglobin equilibrium and chronic β-adrenoceptor blockade in coronary heart disease, 33
JUSKO, W.J. *see* GARDNER, M.J.

KADURY, S. *see* GRIFFITHS, B.E.
KAMPMANN, J.P. & MØLHOLM HANSEN, J.E. Serum protein binding of propylthiouracil, 549
KANARKOWSKI, R. *see* GARDNER, M.J.
KANTO, J. *see* LAURIKAINEN, E.
KAPP, W. *see* FELDMEIER, Ch.
KAPP, W. *see* GEMPERLE, M.
KAPP, W. *see* PHILIPP, E.
KARACAN, I. *see* HARTSE, K.M.
KAYE, C.M. *see* HOLT, J.E.
KELLY, J.G. *see* FINCH, M.B.
KELMAN, A.W. *see* MEREDITH, P.A.
KENDALL, M.J. *see* ROLF SMITH, S.
KHIR, A.S.M. *see* SCOTT, A.K.
KIERULF, P. *see* PIKE, E.
KINNEY, C.D. *see* TAYLOR, D.R.
KIPNOWSKI, J. *see* DÜSING, R.
KIRCH, W., HEIDEMANN, H., SPAHN, H., MUTSCHLER, E. & OHNHAUS, E.E. Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol, 212P
KJAER, M. & NIELSEN, H. The analgesic effect of the GABA agonist THIP in patients with chronic pain of malignant origin. A phase-1-2 study, 477
KLOTZ, U. *see* ZIEGLER, G.
KOENE, R.A.P. *see* HUYSMANS, F.TH.M.
KÖLLMER, H. *see* HEWETT, C.
KONG, I. *see* DEVONSHIRE, H.W.
KOSHOREK, G.L. *see* ROEHERS, T.
KÖSTER, J. *see* AHMAD, F.
KOVACS, I. *see* SOWEMIMO-COKER, S.O.
KRAMER, H.J. *see* DÜSING, R.
KREMERS, P. *see* CRESTEIL, T.
KREUZER, H. *see* HEWETT, C.
KRIEGER, J., MANGIN, P. & KURTZ, D. Effects of midazolam on sleep in normal subjects, 79S
KRISHNA, S. *see* WHITE, N.J.
KRUEGER, H. & MÜLLER-LIMMROTH, W. Residual effects of flurazepam and brotizolam on psychomotor performance, 347S
KUHN, F.J., BÖKE-KUHN, K., DANNEBERG, P., LEHR, E. & STOCKHAUS, K. Pharmacology and hypnogenic properties of brotizolam in animals, 253S
KURTZ, D. *see* KRIEGER, J.

LACHNIT, K.S., PROSZOWSKI, E. & RIEDER, L. Midazolam in the treatment of sleep disorders in geriatric patients, 173S
LAGRUE, G. *see* HOUIN, G.
LAHER, M.S. *see* O'CALLAGHAN W.G.
LAI, C.L. *see* WANG, C.
LAM, K.C. *see* WANG C.
LAPORTE, J.-R., PORTA, M. & CAPELLÀ, D. Drug utilization studies: a tool for determining the effectiveness of drug use, 301
LARUELLE, P. *see* ETIENNE, J.
LASSMANN, A., VON PRITTWITZ, W., URICH, R., LISSNER, R., WOODCOCK, B.G. & RIETBROCK, N. Altered kinetics of drug binding to human serum albumin in chronic uraemia, 221P
LAURIKAINEN, E. & KANTO, J. Saliva concentrations of lignocaine in patients with acute myocardial ischaemia, 199L
LAWRENCE, J.R. *see* MCEWEN, J.
LAZARUS, J.H. *see* GRIFFITHS, B.E.
LEHR, E. *see* KUHN, F.J.
LEISHMAN, B. *see* AMREIN, R.
LEISHMAN, B. *see* ZIEGLER, W.H.
LENNARD, L., REES, C.A., LILLEYMAN, J.S. & MADDOCKS, J.L. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia, 359
LEROUX, L.P. *see* CRESTEIL, T.
LEVIS, G. *see* ILIOPOULOU, A.
LEVY, M., ELDOR, A., ZYLBER-KATZ, E. & ELIAKIM, M. The effect of long-term colchicine therapy in patients with recurrent polyserositis on the capacity of blood platelets to synthesize thromboxane A_2, 191
LEVY, R.H. *see* CENRAUD, B.
LEVY, Y. *see* MARKEL, A.
LEWIS, M.J. *see* SINGH, H.
LICHTERFELD, A. *see* VON DELBRÜCK, O.
LIEN, E. & BAKKE, O.M. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion, 71
LIGHTMAN, S.L. *see* ARMITSTEAD, J.G.
LIJNEN, P. *see* STAESSEN, J.
LILJEKVIST, J. *see* PLYM FORSHELL, G.
LILLEYMAN, J.S. *see* LENNARD, L.
LINZMAYER, L. *see* SALETU, B.

LISSNER, R. *see* LASSMANN, A.
LISTER, R.G. *see* FILE, S.E.
LIVESEY, J.H. *see* GILCHRIST, N.
LOHMANN, H., VON DELBRÜCK, O. & FINDEISEN, P. Comparative studies on the efficacy of brotizolam and nitrazepam: a multi-centre study, 403S
LOISEAU, P. *see* CENRAUD, B.
LOW, R.A. *see* RUBIN, P.C.
LUBSEN, J. *see* SERRUYS, P.W.
LUDWIG, L. *see* ZIEGLER, G.
LUNDE, P.K.M. *see* PIKE, E.
LUPOLOVER, R., BALLMER, U., HELCL, J. ESCHER, J. & PAVLETIC, B. Efficacy and safety of midazolam and oxazepam in insomniacs, 139S

McALLISTER, W.A.C. *see* THOMPSON, P.J.
McBURNEY, A. *see* DEY, N.G.
MacCONNACHIE, A. *see* POTTS, R.C.
McDEVITT, D.G. *see* ARNOLD, J.M.O.
McDEVITT, D.G. *see* FINCH, M.B.
McDEVITT, D.G. *see* FRANCIS R.J.
McDEVITT, D.G. O'CONNOR P.C.
McDEVITT, D.G. *see* TAYLOR, D.R.
MacDONALD, I.A. *see* WILCOX, R.G.
McELWAIN, T.J. *see* NEWELL, D.R.
McEWEN, J., LAWRENCE, J.R. & HILTON, S.A. Sample collection and labelling in human pharmacokinetic studies, 230P
McGARRY, K. *see* O'CALLAGHAN, W.G.
McGOWAN, F.X., NASH, P.V. & BJORNSSON T.D. Assay-dependent kinetics of heparin: evidence for rapid *in vitro* activation of heparin, 677
McINNES, G.T., HELENGLASS, G. & PRENTICE, A.G. Anticoagulant control in medical outpatients, 221P
McINNES, G.T. *see* RAPEPORT, W.G.
MACKAY, I.G., WATSON, M.L. & MUIR, A.L. Prostaglandin synthesis and renal haemodynamics during frusemide induced diuresis, 228P
McKENNA, W.J. *see* HOLT, D.W.
MACKIE, S. *see* DUNK, A.A.
McLAUGHLAN, P. *see* COOMBS, R.R.A.
McMANUS, I.C., ANKIER, S.I., NORFOLK, J., PHILLIPS, M. & PRIEST, R.G. Effects on psychological performance of the benzodiazepine, loprazolam, alone and with alcohol, 291
McNAMARA, P.J. *see* BENEDEK, I.H.
MacPHERSON, P. *see* RAPEPORT, W.G.
McSHARRY, D.R. *see* MEREDITH, P.A.
MADDOCKS, J.L. *see* LENNARD, L.
MAGNUSSON, J.O. Metabolism of digoxin after oral and intrajejunal administration, 741
MAHAJAN, P., PEARSON, R.M., BORODA, C. & TURNER, P. Different fibre preparations on glucose tolerance: problems of comparison, 226P
MAIDMENT, C.G. *see* COOK, P.J.
MALLET, A.I. *see* BARR, R.M.
MAMELAK, M., CSIMA, A. & PRICE, V. Effects of brotizolam on the sleep of chronic insomniacs, 377S
MANGHANI, K.K. *see* EDMONDSTONE, W.M.
MANGIN, P. *see* KRIEGER, J.
MANKODI, N.A. *see* VAIDYA, A.B.
MARIAS, J. *see* SCHERSCHLICHT, R.
MARKEL, A., BROOK, J.G., LEVY, Y., AVIRAM, M. & YOUDIM, M.B.H. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol, 663
MARSHALL, R.W. *see* ABILA, B.
MARUHN, D., WENSING, K. & OHNHAUS, E.E. Effect of antipyrine and phenobarbitone on renal γ-glutamyltransferase excretion in man, 220P
MASCI, E. *see* CALDARA, R.
MASHFORD, M.L. *see* CHING, M.S.
MASON, G., RAWLINS, M.D. & SHUSTER, S. Blood monocyte aryl hydrocarbon hydroxylase activity in psoriasis, 333
MASSANG, J. *see* BELLAMY, G.R.
MASSIAS, P. *see* ADVENIER, C.
MEFFIN, P.J., GRGURINOVICH, N., BROOKS, P.M., MINERS, J.O., COCHRAN, M. & STRANKS, G. Ranitidine disposition in patients with renal impairment, 731
MEINERTZ, T. *see* BECHTOLD, H.
MELORIO, T. *see* ALTAMURA, A.C.
MELOT, CH. *see* RENARD, M.
MENDELOW, A.D. *see* RAPEPORT, W.G.
MEREDITH, P.A., ELLIOTT, H.L. McSHARRY, D.R., KELMAN, A.W. & REID, J.L. The pharmacokinetics of endralazine in essential hypertensives and normotensive subjects, 27
MEYER, B.H., MÜLLER, F.O., CLUR, B.K. & GRIGOLEIT, H.-G. Effects of tendamistate (α-amylase inactivator) or starch metabolism, 145
MIKHAILIDIS, D.P. *see* BARRADAS, M.A.
MILLIGAN, N., OXLEY, J. & RICHENS, A. Acute effects of intravenous phenytoin on the frequency of inter-ictal spikes in man, 285
MILLOT, F. *see* ETIENNE. J.
MILNE, L.A., WILLIAMS, N.E., CALVEY, T.N., MURRAY, G.R. & CHAN, K. Effect of urine pH on the elimination of phenoperidine, 101
MINERS, J.O., ATTWOOD, J. & BIRKETT, D.J. Influence of sex and oral contraceptive steroids on paracetamol metabolism, 503
MINERS, J.O. *see* MEFFIN, P.J.
MINESHITA, S. Influence of gastrectomy on aspirin absorption, 756L
MIRAKHUR, R.K. *see* FERRES, C.J.
MISCH, K.J. *see* BARR, R.M.
MITCHELL, B.G., CLEMENTS, J.A., POTTAGE, A. & PRESCOTT, L.F. Mexiletene disposition: individual variation in response to urine acidification and alkalinisation, 281
MITTELBACH, G. *see* STACHER, G.
MIYATAKE, A. *see* HEAVEY, D.J.
MIZUKI, Y. *see* TANAKA, M.
MOERMAN, E. *see* STAESSEN, J.
MOFFATT, J.A. *see* ARMSTRONG, P.W.
MØLHOLM HANSEN, J.E. *see* KAMPMANN, J.P.
MOLS, P. *see* RENARD, M.
MONTGOMERY, I., OSWALD, I., MORGAN, K. & ADAM, K. Trazodone enhances sleep in subjective quality but not in objective duration, 139
MONTI, J.M., DEBELLIS, J., ALTERWAIN, P. & D'ANGELO, L. Midazolam and sleep in insomniac patients, 87S
MORELAND, T.A. *see* CENRAUD, B.
MORGAN, D.J. *see* CHING, M.S.
MORGAN, K. *see* MONTGOMERY, I.
MORSELLI, P.L. *see* CENRAUD, B.
MOSES, D.K., CHARLES, B.G., RAVENSCROFT, P.J. & WHYTE, I.M. Food reduces the oral bioavailability of propantheline bromide in healthy subjects, 758L
MOULOPOULOS, S. *see* ILIOPOULOU, A.
MUIR, A.L. *see* MACKAY, I.G.

MUIR, A.L. *see* WATHEN, C.G.
MÜLLER, F.O. *see* MEYER, B.H.
MÜLLER, P. *see* DAMMANN, H.G.
MÜLLER-LIMMROTH, W. *see* KRUEGER, H.
MURRAY, G.D. *see* ZOCCALI, C.
MURRAY, G.R. *see* MILNE, L.A.
MURRAY, S. *see* BOOBIS, A.R.
MUTSCHLER, E. *see* KIRCH, W.

NAGEL, C. *see* VON DELBRÜCK, O.
NAKAMURA, K. *see* HERMAN, R.J.
NAKAYA, H. *see* ISHIZAKI, T.
NAKIELNY, R. *see* CHANNER, K.S.
NANDI, K.L. *see* JOCHEMSEN, R.
NASH, P.V. *see* MCGOWAN, F.X.
NAYLOR, C. *see* COSTA E SILVA, J.A.
NEBOUT, TH. *see* HOUIN, G.
NELSON, G.I.C. *see* SILKE, B.
NEWBY, S.N. *see* BACK, D.J.
NEWELL, D.R., CALVERT, A.H., HARRAP, K.R. & MCELWAIN, T.J. The clinical pharmacology of chlorambucil and prednimustine, 762L
NICHOLAS, V. *see* DÜSING, R.
NICHOLLS, J.T. *see* CASTLE, W.M.
NICHOLLS, M.G. *see* GILCHRIST, N.
NICHOLSON, A.N. Foreword, 1S
NICHOLSON, A.N. & STONE, B.M. Midazolam: Sleep and performance studies in middle age, 115S
NICHOLSON, A.N. Foreword, 201S
NICHOLSON, A.N. Brotizolam: studies of effects on sleep and on performance in young adulthood and in middle age, 365S
NICHOLSON, A.N. Brotizolam: review of clinical studies, 433S
NIELSEN, H. *see* KJAER, M.
NIGGESCHULZE, A. *see* HEWETT, C.
NORFOLK, J. *see* MCMANUS, I.C.
NOTARIANNI, L.J. *see* BENNETT, P.N.

OBLOWITZ, H. & ROBINS, A.H. The effect of clobazam and lorazepam on the psychomotor performance of anxious patients, 95
O'BRIEN, E. *see* O'CALLAGHAN, W.G.
O'CALLAGHAN, W.G., LAHER, M.S., MCGARRY, K., O'BRIEN, E. & O'MALLEY, K. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients, 417
OCHS, H.R. & GREENBLATT, D.J. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation, 743
O'CONNOR, P.C., ARNOLD, J.M.O., FINCH, M.B., GALLOWAY, D.G., FRANCIS, R.J., HARRON, D.W.G., MCDEVITT, D.G. & SHANKS, R.G. Effects of Ro 31-1118, a new cardioselective β-adrenoceptor antagonist on exercise and isoprenaline responses in man, 211P
O'CONNOR, P.C. *see* FRANCIS, R.J.
OGADA, T. *see* JUMA, F.
OHNHAUS, E.E. *see* KIRCH, W.
OHNHAUS, E.E. *see* MARUHN, D.
OKOLI, R.C. *see* SILKE, B.
O'MALLEY, K. *see* O'CALLAGHAN, W.G.
O'REILLY, R. *see* BANFIELD, C.
ORME, M.C.L'E. *see* BACK, D.J.
OSUAFOR, T.O.K. *see* DUNK, A.A.
OSWALD, I. *see* MONTGOMERY, I.
OXLEY, J. *see* MILLIGAN, N.
OYAMA, Y. *see* ISHIZAKI, T.

PAALZOW, L. *see* IBRAHEEM, J.J.
PANDIT, S.K. *see* FERRES C.J.
PAPE J. *see* BREIBY M.
PARK, B.K. *see* BACK, D.J.
PARK, B.K. *see* RAPEPORT, W.G.
PARKER, G. & ROBERTS, C.J.C. Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease, 259
PARKER, G. *see* DANESHMEND, T.K.
PARNHAM, A.J. *see* GIBB, I.
PASSERON, D. *see* DU CAILAR, J.
PATEL, D.K. *see* BENNETT, P.N.
PATHY, M.S.J. *see* BAYER, A.J.
PAUL, T. *see* VAIDYA, A.B.
PAVELETIC, B. *see* LUPOLOVER, R.
PEARSON, R.M. *see* MAHAJAN, P.
PEREIRA, L. *see* FEELY, J.
PERSSON, B. *see* HEDNER, T.
PETRIE, J.C. *see* SCOTT, A.K.
PHILLIP, E. & KAPP, W. Comparative study of midazolam and Vesparax in moderate or severe insomnia in female surgical patients, 161S
PHILLIPS, M. *see* MCMANUS, I.C.
PHILLIPS, R.J.W. *see* ROBINSON, B.F.
PICKLES, H. *see* SOWEMIMO-COKER, S.O.
PIERCE, D.M. & FRANKLIN, R.A. The classification of benzodiazepine hypnotics, 345L
PIERI, L. Preclinical pharmacology of midazolam, 17S
PIERON, R. *see* ETIENNE, J.
PIKE, E., KIERULF, P., SKUTERUD, B., BREDESEN, J.E. & LUNDE, P.K.M. Drug binding in sera deficient in lipoproteins, albumin or orosomucoid, 233
PINDER, R.M. Mianserin pharmacokinetics—a reply 202L
PLYM FORSHELL, G., GUNNARSSON, P.O. & LILJEKVIST, J. On the clinical pharmacology of prednimustine, 760L
POPOVICIU, L. & CORFARIU, O. Efficacy and safety of midazolam in the treatment of night terrors in children, 97S
PORTA, M. *see* LAPORTE, J.-R.
POTTAGE, A. *see* MITCHELL, B.G.
POTTS, R.C., MACCONNACHIE, A., BROWN, R.A., GIBBS, J.H., ROBERTSON, A.J., HASSAIN, H.A.A. & SWANSON BECK, J. Some tetracycline drugs suppress mitogen-stimulated lymphocyte growth but others do not, 127
POWERS, K. *see* RENWICK, A.G.
PRATT, J. *see* JENNER, P.
PREISS, D. & BERGUSON, P. Dose–response studies on glycopyrrolate and atropine in conscious cardiac patients, 523
PRENTICE, A.G. *see* MCINNES, G.T.
PRESCOTT, L.F. *see* MITCHELL, B.G.
PRICE, V. *see* MAMELAK, M.
PRIEST, R.G. *see* MCMANUS, I.C.
PROSZOWSKI, E. *see* LACHNIT, K.S.
PURBA, H.S. *see* BACK, D.J.

QUARTERMAN, C.P. *see* JACK, D.B.
QUATTRONE, A., TEDESCHI, G., AGUGLIA, U., SCOPACASA, F., DIRENZO, G.F. & ANNUNZIATO, L. Prolactin secretion in man: a useful tool to evaluate the

activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine, 471

RABAGO-SÁNCHEZ, J. *see* FRITZ-OSNER, A.
RAMSAY, L.E. & FREESTONE, S. Addition of xipamide to bendrofluazide: no added antihypertensive effect, 208P
RAMSAY, L.E. & FREESTONE, S. Preliminary evaluation of pinacidil in hypertension, 336
RANE, A. *see* SÄWE, J.
RAPEPORT, W.G., McINNES, G.T., THOMPSON, G.G., FORREST, G., PARK, B.K. & BRODIE, M.J. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine, 133
RAPEPORT, W.G., MENDELOW, A.D., McPHERSON, P., FRENCH, G., THOMPSON, G.C., AGNEW, E. & BRODIE, M.J. Plasma protein binding and CSF concentrations of valproic acid following acute oral dosing, 225P
RAPEPORT, W.G., MENDELOW, A.D., FRENCH, G., MacPHERSON, P., TEASDALE, E., AGNEW, E., THOMPSON, G.G. & BRODIE, M.J. Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing, 365
RAPEPORT, W.G. *see* BRODIE, M.J.
RAVENSCROFT, P.J. *see* MOSES, D.K.
RAWLINS, M.D. *see* BATEMAN, D.N.
RAWLINS, M.D. *see* MASON, G.
RAY, D.K. *see* VAIDYA, A.B.
RAYMOND K. *see* CHING, M.S.
REES, C.A. *see* LENNARD, L.
REID, J.L. *see* RUBIN, P.C.
REID, J.L. *see* STRUTHERS, A.D.
RENARD, M., JACOBS PH., MOLS, P., MELOT, CH., DRESSE, A. & BERNARD, R. The effective plasma concentrations of sulmazol (AR-L 115 BS) on haemodynamics in chronic heart failure, 313
RENNER, E. *see* EVERS, J.
RENTON, K.W. *see* GRAY, J.D.
RENWICK, A.G., HIGGINS, V., POWERS, K., SMITH, C.L. & GEORGE, C.F. The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment, 77
RENWICK, A.G. *see* SMITH, R.S.
REYNOLDS, B. *see* RUBIN, P.C.
REYNOLDS, E.H. *see* JENNER, P.
REYNOLDS, E.H. *see* SHORVON, S.D.
RHODES, J. *see* DEW, M.J.
RICHARD, A. *see* COLUSSI, D.
RICHARDS, M. *see* GRENNAN, D.M.
RICHARDSON, M.D. *see* DANESHMEND, T.K.
RICHENS, A. *Editorial*, Standard units for expressing drug concentrations in biological fluids, 1
RICHENS, A. *see* ABILA, B.
RICHENS, A. *see* MILLIGAN, N.
RICHMOND, C.R. *see* BELL, G.D.
RICHTER, E. *see* JOCHEMSEN, R.
RIEDER, L. *see* LACHNIT, K.S.
RIETBROCK, N. *see* ASTHANA, O.P.
RIETBROCK, N. *see* LASSMANN, A.
RIMMER, A. *see* SINGH, H.
RITTMEYER, P. *see* AHMAD, F.
ROBERTS, C.J.C. *see* DANESHMEND, T.K.
ROBERTS, C.J.C. *see* PARKER, G.
ROBERTSON, A.J. *see* POTTS, R.C.
ROBERTSON, J.I.S. *see* ZOCCALI, C.
ROBINS, A.H. *see* OBLOWITZ, H.
ROBINSON, B.F., DOBBS, R.J. & PHILLIPS, R.J.W. Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension, 327
RODRÍGUEZ-TENORIO, A. *see* FRITZ-OSNER, A.
ROEHERS, T., ZORICK, T., KOSHOREK, G.L., WITTING, R. & ROTH, T. Effects of acute administration of brotizolam in subjects with disturbed sleep, 371S
ROFFE, D. *see* BELLAMY, G.R.
ROGERS, H.J. *see* WOOLF, A.D.
ROGOWSKI, Z. *see* GATH, I.
ROLF SMITH, S., KENDALL, M.J., WORTHINGTON, D.J. & HOLDER, R. Can the biochemical responses to a β_2-adrenoceptor stimulant be used to assess the selectivity of β-adrenoceptor blockers? 557
ROSE, J.D.R. *see* GLEESON, D.
ROTH, T. *see* HAURI, P.
ROTH, T. *see* ROEHERS, T.
ROTHWELL, K. *see* BELL, G.D.
ROUD, H.K. *see* GILCHRIST, N.
ROUX, A. *see* ADVENIER, C.
ROWLAND, M. *see* BANFIELD, C.
ROWLAND, M. *see* BECHTOLD, H.
RUBIN, P.C., BUTTERS, L., LOW, R.A. & REID, J.L. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension, 543
RUBIN, P.C., BUTTERS, L., REYNOLDS, B., EVANS, J., SUMNER, D., LOW, R.A. & REID, J.L. Atenolol elimination in the neonate, 659
RUBIN, P.C. *see* BRYSON, S.M.
RYDER, R.E.J. *see* DEW, M.J.

SALAKO, L.A. *see* WALKER, O.
SALETU, B., GRÜNEBERGER, J. & LINZMAYER, L. Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers, 333S
SALOM, M. *see* BECK, H.
SÁNCHEZ-MARTINEZ, J. *see* FRITZ-OSNER, A.
SANKEY, M.G. *see* HOLT, J.E.
SASAKI, T. *see* ISHIZAKI, T.
SATEIA, M. *see* HAURI, P.
SATO, T. *see* ISHIZAKI, T.
SÄWE, J., SVENSSON, J.O. & RANE, A. Morphine metabolism in cancer patients on increasing oral doses—no evidence for autoinduction or dose–dependence, 85
SCHALCH, E. *see* ZIEGLER, W.H.
SCHERSCHLICHT, R. & MARIAS, J. Effects of oral and intravenous midazolam, triazolam and flunitrazepam on the sleep–wakefulness cycle of rabbits, 29S
SCHIPPERHEYN, J.J. *see* HENDRIKS, F.F.A.
SCHLÄPPI, B. Safety aspects of midazolam, 37S
SCHNIEDEN, H. Open letter to the Editors, British Journal of Clinical Pharmacology, 115L
SCHNEIDER, C. *see* STACHER G.
SCHOELLER, J.P. *see* COLUSS, D.
SCOLLO-LAVIZZARI, G. Hypnotic efficacy and clinical safety of midazolam in shift-workers, 73S
SCOPACASA, F. *see* QUATTRONE, A.
SCOTT, A.K., KHIR, A.S.M., STEELE, W.H., HAWKSWORTH, G.M. & PETRIE, J.C. Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone, 441

SCOTT, P.J.W. *see* BRYSON, S.M.
SERRUYS, P.W., VANHALEWEYK, G., VAN DEN BRAND, VERDOUW, P., LUBSEN, J. & HUGENHOLTZ, P.G. The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease, 51
SHANKS, R.G. *see* FRANCIS, R.J.
SHANKS, R.G. *see* HARRON, D.W.G.
SHANKS, R.G. *see* O'CONNOR, P.C.
SHARMAN, V.L. *see* VANDENBURG, M.J.
SHAW, M.A. *see* BACK, D.J.
SHERIDAN, D.J. *see* CULLING, W.
SHERLOCK, S. *see* DUNK, A.A.
SHETH, U.K. *see* VAIDYA, A.B.
SHIBUYA, T. *see* ISHIZAKI, T.
SHORVAN, S.D., ELWES, R.D.C., JOHNSON, A.L. & REYNOLDS, E.H. The early treatment and prognosis of epilepsy, 216P
SHORVAN, S.D. *see* JENNER, P.
SHUSTER, S. *see* MASON, G.
SIDDIQUI, M. *see* GRENNAN, D.M.
SILAMUT, K. *see* WHITE, N.J.
SILKE, B., VERMA, S.P., HUSSAIN, M., NELSON, G.I.C., OKOLI, R.C. & TAYLOR, S.H. Haemodynamic dose–response effects of i.v. penbutolol in angina pectoris, 529
SIMON, B. *see* DAMMAN, H.G.
SIMON, P. *see* UZZAN, B.
SINGH, H., RIMMER, A., LEWIS, M.J. & HENDERSON, A.H. β-adrenoceptor hypersensitivity after stopping oxprenolol: discrepant findings not attributable to methodology, 722
SINGH, H. *see* CULLING, W.
SIOUFI, A. *see* COLUSSI, D.
SKUTERUD, B. *see* PIKE, E.
SKYPALA, I. *see* THOMPSON, P.J.
SLEVIN, M.L., AHERNE, G.W., HARVEY, V.J., BARTON, N.K., JOHNSTON, A. & WRIGLEY, P.F.M. Delayed release bleomycin: comparative pharmacology of bleomycin oil suspension and bleomycin in saline, 215P
SLOAN, T.P. *see* DEVONSHIRE, H.W.
SLUITTER, H.E. *see* HUYSMANS, F.TH.M
SMITH, C.L. *see* RENWICK, A.G.
SMITH, P.M. *see* GLEESON, D.
SMITH, R.L. *see* DEVONSHIRE, H.W.
SMITH, R.S., WARREN, D.J., RENWICK, A.G. & GEORGE, C.F. Acebutolol pharmacokinetics in renal failure, 253
SMITH, S.E. *see* GRAINGER, S.L.
SOMERVILLE, K.W. *see* BELL, G.D.
SOWEMIMO-COKER, S.O., KOVACS, I., PICKLES, H., HEDGES, A. & TURNER, P. Dipyridamole increases red cell deformability, 226P
SOWEMIMO-COKER, S.O., KOVACS, I.B., PICKLES, H., HEDGES, A. & TURNER, P. Dipyridamole increases red cell deformability, 423
SPAHN, H. *see* KIRCH, W.
STACHER, G., STEINRINGER, H., WINKLEHNER, S., MITTELBACH, G. & SCHNEIDER, C. Effects of graded oral doses of meptazinol and pentazocine in comparison with placebo on experimentally induced pain in healthy humans, 149
STAESSEN, J., CATTAERT, A., DE SCHAEPDRYVER, A., FAGARD, R., LIJNEN, P., MOERMAN, E. & AMERY, A. Effects of β_1-adrenoceptor agonism or plasma renin activity in normal men, 553
STANIFORTH, D.H. The QT interval and cycle length: the influence of atropine, hyoscine and exercise, 615
STEELE, W.H. *see* SCOTT A.K.
STEINRINGER, H. *see* STACHER G.
STEVENSON, I.H. *see* SWIFT C.G.
STEWART M.J. & WATSON, I.D. *Editorial.* Standard units for expressing drug concentrations in biological fluids, 3
STOCKHAUS, K. *see* KUHN, F.J.
STONE B.M. *see* NICHOLSON, A.N.
STOREY, G.C.A. *see* HOLT, D.W.
STÖTZER, H. *see* HEWETT C.
STRANKS, G. *see* MEFFIN, P.J.
STRUTHERS, A.D. & REID, J.L. Nifedipine does not influence adrenaline induced hypokalaemia in man 342L
SUGANUMA T. *see* ISHIZAKI, T.
SUMNER, D. *see* RUBIN, P.C.
SUNDSFJORD, J. *see* BREIBY, M.
SVENSSON, J.O. *see* SÄWE, J.
SWANSON BECK, J. *see* POTTS, R.C.
SWIFT, C.G., SWIFT, M.R., HAMLEY, J., STEVENSON, I.H. & CROOKS, J. CNS effects of chronic benzodiazepine hypnotic ingestion in the elderly, 217P
SWIFT, M.R. *see* SWIFT, C.G.
SYBRECHT, G.W. Influence of brotizolam on the ventilatory and mouth-occlusion pressure response to hypercapnia in patients with chronic obstructive pulmonary disease, 425S

TANAKA, M., ISOZAKI, H., MIZUKI, Y. & INANAGA, K. Effect of brotizolam on the averaged photopalpebral reflex in man, 325S
TATTERSFIELD, A.E. & CRAGG, D.J.B. Effect of ICI 118551 on bronchial β-adrenoceptor function and exercise heart rate in normal man, 224P
TATTERSFIELD, A.E. & CRAGG, D.J. Effect of ICI 118551 on bronchial β-adrenoceptor function and exercise heart rate in normal man, 587
TAYLOR, D.R., DUFFIN, D., KINNEY, C.D. & MCDEVITT, D.G. Investigation of diurnal changes in the disposition of theophylline, 413
TAYLOR, D.R., KINNEY, C.D. & MCDEVITT, D.G. Prediction of maintenance oral theophylline dosage using single oral doses in patients with obstructive airways disease, 511
TAYLOR, S.H. *see* SILKE, B.
TAYLOR, W.B. & BATEMAN, D.N. High dose metoclopramide—preliminary pharmacokinetic studies, 341L
TEASDALE, E. *see* RAPEPORT, W.G.
TEDESCHI, G. *see* QUATTRONE, A.
TFELT-HANSEN, P. *see* IBRAHEEM, J.J.
THERON, M. *see* HILAIRE, J.
THIEN, TH. *see* HOFFMANN, J.J.M.L.
THIEN, TH.A. *see* HUYSMANS, F.TH.M.
THIJSSEN, H.H.W. & BAARS, L.G. Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? 491
THOMPSON, G.G. *see* RAPEPORT, W.G.
THOMPSON, P.J., SKYPALA, I., DAWSON, S., MCALLISTER, W.A.C. & TURNER WARWICK, M. The effect of diet upon serum concentrations of theophylline, 267
THOMPSON, R. *see* GRENNAN, D.M.
THOMPSON, A. *see* WARREN, J.B.
THORNBY, J.I. *see* HARTSE, K.M.
TILLEMENT, J.P. *see* HOUIN, G.

TITTOBELLO, A. *see* CALDARA, R.
TJIA, J.F. *see* BACK, D.J.
TORNATORE, K.M. *see* GARDNER, M.J.
TRENK, D. *see* BECHTOLD, H.
TUCKER, G.T. *see* HOLT, D.W.
TURNER, C. *see* WARREN, J.B.
TURNER, P. *see* JACKSON, S.H.D.
TURNER, P. *see* MAHAJAN, P.
TURNER, P. *see* SOWEMIMO-COKER, S.O.
TURNER WARWICK, M. *see* THOMPSON, P.J.

ULRICH, R. *see* LASSMANN, A.
UZZAN, B., WAROT, D., CHERMAT, P., DANTLO, B., BORNSTEIN, S. & SIMON, P. Hypnotic activity of brotizolam: a study in general practice, 417S

VAIDYA, A.B., RAY, D.K., MANKODI, N.A., PAUL, T. & SHETH, U.K. Phase 1 tolerability and antiamoebic activity studies with 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (GO. 10213): a new antiprotozoal agent, 517
VAN BOXTEL, C.J. *see* JOCHEMSEN, R.
VAN DEN BRAND, M. *see* SERRUYS, P.W.
VANDENBURG, M.J., SHARMAN, V.L., WRIGHT, P., DREW, P.J. & BARNES, J.N. Hydralazine and prazosin in the treatment of hypertension, 537
VANHALEWEYK, G. *see* SERRUYS, P.W.
VAN'T LAAR, A. *see* HOFFMANN, J.J.M.L.
VAROQUAUX, O. *see* ADVENIER, C.
VAUGHAN, N.J.A. *see* ARMITSTEAD, J.G.
VERDOUW, P. *see* SERRUYS, P.W.
VERMA, N. *see* BRYSON, S.M.
VERMA, S.P. *see* SILKE, B.
VIRJEE, J.P. *see* CHANNER, K.S.
VOGEL, F. *see* VOGEL, G.W.
VOGEL, G.W. & VOGEL, F. Effect of midazolam on sleep of insomniacs, 103S
VON DELBRÜCK, O., GOETZKE, E. & LICHTERFELD, A. Efficacy and acceptability of brotizolam in the elderly, 391S
VON DELBRÜCK, O. *see* LOHMANN, H.
VON DELBRÜCK, O., GOETZKE, E. & NAGEL, C. Tolerance studies with brotizolam in hospitalized patients, 385S
VON PRITTWITZ, W. *see* LASSMANN, A.

WALKER, O., DAWODU, A.H., ADEYOKUNNU, A.A., SALAKO, L.A. & ALVAN, G. Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria, 701
WALLE, T. *see* HURWITZ, G.A.
WALLER, J.F. *see* EDMONDSTONE, W.M.
WALT, R.P. *see* DUNK, A.A.
WANG, C., WONG, K.L., LAM, K.C. & LAI, C.L. Ranitidine does not affect gonadal function in man, 430
WARD, J. *see* DEY, N.G.
WARD, S.A. *see* BACK, D.J.
WARNOCK, D.W. *see* DANESHMEND, T.K.
WAROT, D. *see* UZZAN, B.
WARREN, D.J. *see* SMITH, R.S.
WARREN, J.B., TURNER, C., DALTON, N., THOMSON, A., COCHRANE, G.M. & CLARK, T.J.H. The effect of posture on the sympathoadrenal response to theophylline infusion, 405
WARRINGTON, S.J. *see* ANKIER, S.I.
WATERLAND, J. *see* FALCONER, H.D.
WATHEN, C.J., HANNAN, W.J., ADIE, C.J. & MUIR, A.L. A radionuclide method for the simultaneous study of the effects of drugs on central and peripheral haemodynamics, 45
WATSON, I.D. *see* STEWART, M.J.
WATSON, M.L. *see* MACKAY, I.G.
WATTS, D.G. *see* ARMSTRONG, P.W.
WEBB, J.G. *see* HURWITZ, G.A.
WEBER, K.H. *see* DANNEBERG, P.
WEI, Y.H. *see* HONG, C.Y.
WELBERS, I.B. *see* GOETZKE, E.
WENSING, K. *see* MARUHN, D.
WESSELMAN, J.G.J. *see* JOCHEMSEN, R.
WHEATLEY, D. Studies in general practice with brotizolam, 415S
WHITE, N.J., CHANTHAVANICH, P., KRISHNA, S., BUNCH, C. & SILAMUT, K. Quinine disposition kinetics, 399
WHITTEN, B. *see* BELL, G.D.
WHYTE, I.M. *see* MOSES, D.K.
WILCOX, R.G., MACDONALD, I.A. & BENNETT, T. The effects of chronic treatment with metoprolol or propranolol on responses to exercise in hypertensive patients, 212P
WILKINS, M. *see* JACK, D.B.
WILKINSON, G.R. *see* HERMAN, R.J.
WILLIAMS, J. Standardization of units of drug concentration measurement, 115L
WILLIAMS, N.E. *see* MILNE, L.A.
WILLIAMS, R.L. *see* HARTSE, K.M.
WILLIAMSON, R.C.N. *see* COOPER, M.J.
WILSON, J.F. *see* ABILA, B.
WIMBERLEY, P.D. *see* JÜRGENSEN, H.J.
WINKLEHNER, S. *see* STACHER, G.
WITTIG, R. *see* ROEHERS, T.
WONG, K.L. *see* WANG, C.
WOOD, A.J.J. *see* HERMAN, R.J.
WOODCOCK, B.G. *see* ASTHANA, O.P.
WOODCOCK, B.G. *see* LASSMAN, A.
WOOLF, A.D., ROGERS, H.J., BRADBROOK, I.D. & CORLESS, D. Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients, 433
WORTHINGTON, D.J. *see* ROLF SMITH, S.
WRIGHT, P. *see* VANDENBURG, M.J.
WRIGLEY, P.F.M. *see* SLEVIN, M.L.

YOUDIM, M.B.H. *see* MARKEL, A.

ZABLUDOWSKI, J.R. *see* ZOCCALI, C.
ZAR, M.A. & GOOPTU, D. Effect of nifedipine on the contractile response of human colonic muscle, 339L
ZIEGLER, G., LUDWIG, L & KLOTZ, U. Effect of midazolam on sleep, 81S
ZIEGLER, W.H., SCHALCH, E., LEISHMAN, B. & ECKERT, M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites, 63S
ZIEGLER, W.H. *see* CREVOISIER, Ch.
ZIEGLER, W.H. *see* HEIZMANN, P.
ZOCCALI, C., ZABLUDOWSKI, J.R., ISLES, C.G., MURRAY, G.D., INGLIS, G.C., ROBERTSON, J.I.S., FRASER, R. & BALL, S.G. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin and sympathoadrenal function in normal man, 305
ZORICK, F. *see* HAURI, P.
ZORICK, T. *see* ROEHERS, T.
ZYLBER-KATZ, E. *see* LEVY, M.

SUBJECT INDEX

Absorption
  amphotericin B lozenges, 106
  clobazam, 728
  methyldopa, 77
Acebutolol, 253
Acenocoumarol, 491
Acetylator status, 27
α_1-acid glycoprotein
  drug binding, 195
  obesity, 751
  plasma concentration, 344L
Adrenaline, 405
β-adrenoceptors
  antagonists
    essential tremor, 210P
    function indicator, 167
    Ro 31-1118
      effects, 211P
      pharmacokinetics, 210P
    blockade
      atenolol, 17
      coronary heart disease. 33
      hypoglycaemia, 718
      oxygen uptake, 557
  function, 224P
  hypersensitivity, 722
  plasma renin, 553
  stimulation, 557
Age
  disopyramide, 344L
  frusemide, 207P, 391
  piroxicam, 433
Albumin
  disopyramide, 344L
  drug binding, 233
Alcohol, 291
Aldosterone, 305
'Allergic' cough, 224P
Alinidine, 451
Ambulatory blood pressure, 9
Amiodarone, 206P
5-aminosalicylic acid
  colonic release, 185
  jejunal instillation, 738
Amphotericin B lozenges, 106
Ampicillin, 691
α-amylase inactivator, 145
Analgesia, 477
Angina, 529
Angiotensin, 305
Anticoagulant control, 221P
Anticonvulsant drugs, 215P
Antihypertensive effect, 208P
Antiprotozoal agent, 517
Antipyrine
  antimalarials, 497
  carbamazepine, 133
  clearance, 759L
  γ-glutamyltransferase excretion, 220P
  ketoconazole, 225P
Anxious patients, 95
AQ-A 39, 627
Arachidonic acid, 715
AR-L 115 BS *see* Sulmazol
Aspirin
  absorption, 756L
  overdose, 219P
Astemizole
  antipyrine, 759L
  indocyanine green, 241
Atenolol
  elimination, 659
  hypertension
    dose ranging, 17
    elderly patients, 417
    forearm resistance, 327
    platelet aggregation, 663
  inflammatory disease, 212P
Atropine
  dose-response
    cardiac patients, 523
    healthy volunteers, 623
  isoprenaline, 175
  QT interval, 615
Autoinduction, 85

BCG, 735
Bemetizide, 377
Bendrofluazide, 208P
Benzodiazepines
  classification, 345L
  CNS effects, 217P
  midazolam, 11S
Bile
  flow, 570
  ibuprofen, 229P
Binding, 109
Bioavailability
  ergotamine, 695
  propantheline, 758L
Bleomycin, 215P
Blood pressure
  atenolol, 17
  isoprenaline, 175
  ketanserin, 305
  prizidilol, 591
  theophylline, 405
Brotizolam, *see* Supplement 2, pp. 201S–442S
  α_2-adrenoceptors, 205S
  auditory awakening threshold, 355S
  biological activity, 231S
  breathing control, 245S

chemical structure, 231S
chronic obstructive pulmonary disease, 425S
cirrhosis, 315S
diazepines, 231S
efficacy
  nitrazepam, 397S
  triazolodiazepines, 407S
elderly patients
  efficacy, 391S
  pharmacokinetics, 299S
electroencephalography, 377S
elimination half-life, 285S
flunitrazepam
  efficacy, 397S
  pre-operative hypnotic, 419S
flurazepam
  auditory arousal threshold, 355S
  psychomotor performance, 347S
general practice, 415S, 417S
healthy volunteers, 285S, 291S
5-hydroxytryptamine, 205S
hypercapnia, 425S
hypnogenic properties, 253S
hypnotics
  biological activity, 231S
  efficacy, 403S, 407S
  elderly, 391S
  general practice, 417S
  photopalpebral reflex, 325S
  pre-operative, 419S
  tolerance, 385S
insomnia
  acute administration, 371S
  chronic, 377S
  efficacy, 407S
  general practice, 415S
  multi-centre study, 413S
intravenous administration, 285S
latency sleep, 355S
metabolism
  animal, 261S
  human, 279S
middle age
  effect studies, 365S
  efficacy, 403S
nitrazepam, 403S
noradrenaline, 205S
oral administration, 285S, 291S
paradoxical sleep, 205S
performance
  age, 365S
  healthy volunteers, 333S
pharmaco-EEG, 333S
pharmacokinetics
  animal, 261S
  cirrhosis, 315S
  clinical, 277S
  comparative, 291S
  elderly, 299S
  human, 279S
  renal failure, 309S
pharmacology, 253S
photopalpebral reflex, 325S
psychomotor performance, 347S
renal failure, 309S
residual effects, 347S
respiratory monitoring, 245S
sleep
  age, 365S
  chronic insomnia, 377S
  disturbance, 403S
  hospitalized patients, 385S
tolerance
  elderly, 391S
  flunitrazepam, 397S
  hospitalized patients, 385S
  triazolodiazepines, 407S
toxicology, 267S
triazolam
  efficacy, 407S
  pharmacokinetics, 291S
young subjects
  pharmacokinetics, 299S
  sleep and performance, 365S
Bufuralol, 218P

Cancer patients, 85
Carbamazepine
  epilepsy, 747
  enzyme induction, 133
Cardiac output, 707
Cardiovascular effects
  alinidine, 451
  AQ-A 39, 627
Cerebral blood flow, 707
Chlorambucil, 762L
Chloroquine
  antipyrine metabolism, 497
  plasma concentrations, 701
Chlorthalidone, 327
Chronic heart failure, 313
Chronic pain, 477
Cimetidine
  intragastric acidity, 461L
  tolbutamide kinetics, 438
Clinical pharmacology, 351
Clobazam
  absorption, 728
  psychomotor performance, 95
Clonidine, 451
CNS effects
  benzodiazepines, 217P
  zopiclone, 259
Coeliac disease, 77
Colchicine, 191
Colon
  5-aminosalicylic acid release, 185
  epithelia, 213P
  muscle, 339L
Colpermin, 228P
Congestive cardiac failure, 385
Conjugation, 77
Contraceptive, 503
Contractile responses, 339L
Coronary arteries
  disease, 51
  surgery, 523
Coronary heart disease, 33

Cortisol, 305
Crohn's disease
  5-aminosalicylic acid, 738
  methyldopa, 77
CSF concentration, 365
Cyclic AMP, 405
Cyclophosphamide, 61
Cytochrome P-450, 651

DAMME, 465
Debrisoquine
  bufuralol oxidation, 218P
  phenacetin disposition, 157
Delta-aminolaevulinic acid synthase, 133
Desethylchloroquine, 701
Desmethylimipramine, 427
Diacetolol, 253
Diazemuls, 448
Diazepam
  premedication, 448
  zopiclone, 216P
Diazepines, 231S
Diclofensine, 427
Diet, 267
Digoxin
  indomethacin interaction, 212P
  metabolism, 741
  plasma concentrations, 445
  skeletal muscle binding, 109
Diprophylline levels, 223P
Dipyridamole, 423
Disopyramide
  administration, 71
  protein binding, 344L
Dithranol, 71S
Diuresis, 228P
Diurnal changes, 413
Dose-dependence, 85
Dose–response
  cardiac patients, 523
  healthy volunteers, 623
Doxycycline, 245
Drug binding
  chronic uraemia, 221P
  deficient sera, 233
  enzyme induction, 195
  obesity, 751
Drugs
  concentration
    standard units, 1, 3, 115L
  disposition, 281
  epidemiology, 351
  metabolism, 735
  oxidation, 460L
  utilization, 301

Efficacy, 301
Elderly patients
  benzodiazepines, 217P
  chlorthalidone, 755L
  hypertension, 417
  ketoprofen, 65
  trazodone, 371
  valproic acid, 104

Elimination
  atenolol, 659
  phenoperidine, 101
Endoscopy, 448
Endralazine
  hypertension, 39
  pharmacokinetics, 27
Enzyme induction
  carbamazepine, 133
  oxazepam pharmacokinetics, 441
  rifampicin, 195
  tricyclic antidepressants, 651
Epilepsy
  carbamazepine, 747
  early treatment, 216P
  oxazepam pharmacokinetics, 441
  phenytoin, 285
  prognosis, 216P
  tryptophan levels, 215P
Epoprostenol, 707
Ergotamine, 695
Erythrocyte binding, 245
Essential hypertension
  endralazine
    intravenous, 39
    pharmacokinetics, 27
  hydralazine, 537
  prazosin, 537
Exercise
  AQ-A 39, 627
  noradrenaline, 599
  oxygen uptake, 319
  propranolol, 599
  QT interval, 615
  Ro 31-1118, 211P
Experimentally induced pain, 149

Fab antibody fragments, 445
Fenfluramine
  platelet aggregation, 459L
  prolactin secretion, 471
Fit frequency, 285
Flecainide acetate, 51
Flunitrazepam
  efficacy, 397S
  pre-operative hypnotic, 419S
  sleep-wakefulness, 29S
Flurazepam
  auditory arousal threshold, 355S
  psychomotor performance, 347S
Food intake, 728
Forearm resistance, 327
Frusemide
  diuresis, 228P
  hypertension, 561
  pharmacokinetics, 207P, 391

GABA agonist, 477
Gastrectomy, 756L
Gastric acid secretion, 112
Gastric secretion, 112
Gelatin capsules, 456
Glomerular filtration rate, 691
Glucagon, 456
Glucose tolerance, 226P

γ-glutamyltransferase excretion, 220P
Glyceryl trinitrate
  haemodynamics, 45
  pharmacokinetics, 205P
Glycine depletion, 219P
Glycopyrrolate, 523
Go. 10213, 517
Gonadal function, 430

Haemodynamics
  flecainide, 51
  glyceryl trinitrate, 205P
  isosorbide dinitrate, 205P
  penbutolol, 529
  radionuclide study, 45
Heart rate
  dose-response, 623
  ICI 118551, 224P
  isoprenaline, 175
Heparin
  kinetics, 677
  LPL activity, 712
Hepatic microsomal enzyme activity, 200L
High fibre diets, 226P
High performance liquid chromatography
  diprophylline, 223P
  hydrochlorothiazide, 222P
Histamine, 214P
Hormonal effects, 465
Hormonal response, 718
H_1 receptor blockade, 241
Hydralazine
  hypertension, 537
  radionuclide study, 45
Hydrochlorothiazide plasma levels, 222P
6-β-hydroxycortisol, 133
α-hydroxymetoprolol, 188
5-hydroxytryptamine
  ketanserin
    essential hypertension, 121
    normal man, 305
  prolactin secretion, 471
Hyoscine
  heart rate, 623
  QT interval, 615
Hypersensitivity, 722
Hypertension
  atenolol, 17
  exercise response, 212P
  forearm resistance, 327
  frusemide, 561
  ketanserin, 121
  labetalol, 9
  penbutolol, 561
  pinacidil, 336
  platelet aggregation, 663
  prazosin, 543
Hypertensive crisis, 725
Hyperthyroidism, 609
Hypnotics, 5S
Hypoglycaemia, 718
Hypokalaemia, 342L

Ibopamine, 112

Ibuprofen
  glycoprotein concentrations, 229P
  rheumatoid arthritis, 214P
ICG clearance, 117
ICI 118551, 224P
Immunoassay, 445
Indocyanine green, 241
Indomethacin
  bemetizide interaction, 377
  digoxin interaction, 212P
Induction, 565
Inflammatory disease, 212P
Inotropic drug, 313
Interactions
  cimetidine—tolbutamide, 438
  indomethacin
    bemetizide, 377
    digoxin, 212P
  phenylbutazone—warfarin, 669
Interconversion, 683
Inter-ictal spikes, 285
Intradermal antigen challenge, 214P
Intragastric acidity, 461L
Intrajejunal administration, 741
Intravenous infusion, 71
Intravenous isoprenaline bolus, 175
Irritable bowel syndrome, 228P
Isoniazid, 743
Isoprenaline, 211P
Isosorbide dinitrate, 205P

Jejunal instillation, 738

Kenyan Africans, 61
Ketanserin
  hypertension, 121
  normal man, 305
Ketoconazole, 225P
Ketoprofen, 65
Kinetics, 677

Labetalol, 9
Left ventricular function, 609
Leukaemia, 359
Lignocaine, 199L
Lilly Prize Lecture, 351
Lipoproteins, 233
Liver
  blood flow, 117
  disease, 259
Loprazolam
  microsomal enzyme activity, 200L
  psychomotor performance, 291
Lorazepam
  psychomotor performance, 95
  tolerance, 645
LPL activity, 712
Lymphocyte growth, 127

Malaria, 701
Meptazinol, 149
6-mercaptopurine, 359
Metabolic clearance, 465
Metabolism, 741

Metabolites, 491
Methyldopa, 77
Metoclopramide, 341L
Metoprolol
  exercise, 212P
  inflammatory disease, 212P
  metabolism, 188
Mexiletine, 281
Mianserin
  metabolites, 201L
  pharmacokinetics, 202L
Midazolam, *see* Supplement 1, pp. 1S–200S
  anaesthesia, 187S
  bioavailability, 43S
  clinical studies, 151S
  dosage studies, 133S
  efficacy
    children, 97S
    hospitalized patients, 157S
    insomniacs, 139S
    out-patients, 179S
    sleep disorders, 167S
  geriatric patients
    dosage studies, 133S
    sleep disorders, 173S
  hospitalized patients
    comparative study, 161S
    efficacy and safety, 157S
    insomnia, 145S
  hydroxy metabolites, 63S
  hypnotic efficacy
    pre-surgical patients, 129S
    shift-workers, 73S
  insomnia
    efficacy, 139S
    hospitalized patients, 145S, 161S
    performance evaluation, 109S
    polygraphic recording, 89S
    safety, 139S
    sleep, 87S, 103S
  middle age, 115S
  night terrors, 97S
  out-patients, 179S
  performance evaluation
    insomniacs, 109S
    middle age, 115S
  pharmacokinetics, 43S
  pharmacology, 17S
  plasma concentration, 51S
  properties, 11S
  psychomotor performance, 121S
  safety
    aspects, 37S
    children, 97S
    hospitalized patients, 157S
    insomniacs, 139S
    shift-workers, 73S
    sleep disorders, 167S
  sedation, 121S
  sleep
    disorders, 81S, 167S
    geriatric patients, 173S
    insomniacs, 87S, 103S, 109S
    middle age, 115S
    normal subjects, 79S
    subjective aspect, 121S
  sleep-wakefulness, 29S
  structure, 11S
Migraine, 695
Milk proteins, 213P
Mitochondrial inhibitors, 487
Monocyte aryl hydrocarbon hydoxylase, 333
Morphine, 85
Mucus glycoprotein, 229P
Myocardial ischaemia, 199L

Nadolol, 417
Naloxone, 718
Neonate, 659
Neuromuscular blocking, 218P
Neutropenia, 359
Nifedipine
  colonic muscle, 339L
  hypertensive crisis, 725
  hypokalaemia, 342L
Nitrazepam, 403S
Nitroglycerin, 385
Nomogram, 511
Non-steroidal anti-inflammatory drugs, 633
Noradrenaline
  brotizolam, 205S
  ketanserin, 305
  plasma level, 599
  theophylline, 405

Obesity, 751
Obstructive airways disease, 511
Oesophageal peristalsis, 456
Open letter, 115L
Oral administration
  digoxin metabolism, 741
  ergotamine, 695
Oral contraceptives
  steroid glucuronides, 227P
  theophylline disposition, 271
Orosomucoid, 233
Outpatients, 221P
Oxazepam
  clinical studies, 151S
  conjugation, 743
  efficacy and safety, 157S
  insomnia, 145S
  pharmacokinetics, 441
Oxprenolol, 722
Oxygen uptake, 319
Oxyhaemoglobin equilibrium, 33
Oxidation
  inhibition, 218P
  status, 157

Pancuronium, 218P
Paracetamol, 503
Paradoxical sleep, 205S
Patient care, 351
Penbutolol
  angina pectoris, 529
  hypertension, 561
Pentazocine, 149

Peppermint oil capsules, 228P
PGE_2, 715
Pharmacodynamics, 371
Pharmacokinetics
  acebutolol, 253
  age, 207P, 391
  5-aminosalicylic acid, 738
  amiodarone, 206P
  ampicillin, 691
  antipyrine, 497
  atenolol, 212P
  chloroquine, 497
  chlorthalidone, 755L
  cimetidine, 438
  cyclophosphamide, 61
  diet, 267
  diurnal changes, 413
  doxycycline, 245
  elderly
    piroxicam, 433
    trazodone, 371
    valproic acid, 104
  endralazine, 27
  epileptics, 441
  frusemide, 207P, 391
  glyceryl trinitrate, 205P
  hypertension, 27
  hypnotic choice, 5S
  ibuprofen, 214P
  inflammatory disease, 212P
  interaction
    cimetidine-tolbutamide, 438
    primaquine-chloroquine, 497
  isosorbide dinitrate, 205
  jejunal instillation, 738
  Kenyan Africans, 61
  ketoprofen, 65
  metoclopramide, 341L
  metoprolol, 212P
  middle-age, 433
  normal, 27
  oxazepam, 441
  piroxicam, 433
  posture, 497
  quinine, 399
  renal failure, 253
  renal insufficiency, 245
  rheumatoid arthritis, 214P
  Ro 31-1118, 210P
  theophylline
    diet, 267
    diurnal changes, 413
  tolbutamide, 438
  trazodone, 371
  valproic acid, 104
  young
    piroxicam, 433
    valproic acid, 104
Pharmacokinetic studies, 230P
Pharmacology, 760L, 762L
Phenacetin, 157
Phenobarbitone, 220P
Phenoperidine, 101
Phenylbutazone, 669
Phenytoin, 285
Phototoxicity, 633
Physiological finger tremor, 167
Pinacidil, 336
Piroxicam, 433
Plasma
  binding, 245
  concentrations, 344L
  levels, 599
  renin activity
    β_1-adrenoceptor agonism, 553
    atenolol, 17
Platelet aggregation
  atenolol, 663
  fenfluramine, 459L
Polymorphism, 188
Post-marketing surveillance, 581
Posture
  ampicillin, 691
  theophylline, 405
PQ intervals, 206P
Practolol
  finger tremor, 167
  isoprenaline, 17S
Prazosin
  hypertension, 537
  pregnancy, 543
Prednimustine, 760L, 762L
Pregnancy
  prazosin, 543
  ritodrine, 209P
Premedication, 448
Prenalterol, 553
Primaquine, 497
Prizidilol, 591
Prolactin, 471
Propantheline, 758L
Propranolol
  exercise, 212P
  finger tremor, 167
  isoprenaline, 17S
  metabolism, 565
  plasma levels, 599
Propylthiouracil, 549
Prostaglandins
  levels, 715
  synthesis, 228P
Protein binding
  disopyramide, 344L
  prophylthiouracil, 549
  valproic acid, 365
Psoriasis, 333
Psychological performance, 291
Psychomotor testing, 645
Psychomotor performance, 95
Pulmonary function, 591
QT interval, 615

Quinine, 399

Radionuclide assessment, 45
Ranitidine
  chronic liver disease, 117
  disposition, 731

gonadal function, 430
intragastric acidity, 461L
Rebound effects, 139
Rectal administration, 695
Recurrent polyserositis, 191
Red cell deformability, 423
Renal blood flow, 417
Renal failure
acebutolol, 253
brotizolam, 309S
digoxin, 109
Renal function, 377
Renal haemodynamics, 228P
Renal impairment, 731
Renal insufficiency, 245
Renal plasma flow, 691
Renin, 305
Rheumatoid arthritis, 214P
Rifampicin
enzyme induction, 195
propranolol metabolism, 565
Ritodrine hydrochloride, 209P
Ro 31-1118
exercise, 211P
pharmacokinetics, 210P
RU31158, *see* Loprazolam

Salicylates, 570
Saliva concentrations, 199L
Sample collecting, 230P
Selection of drugs, 301
Sensory mechanisms, 639
Serum albumin, 221P
Sex difference, 503
Skeletal muscle, 109
SK & F 92657, *see* Prizidilol
Sleep, 139
Smoking, 271
Sodium cromoglycate, 639
Sperm motility, 487
Starch metabolism, 145
Stereochemistry, 669
Steroids, 503
Steroid glucuronides, 227P
Sulmazol, 313
Sulphaphenazole, 460L
Supplements
brotizolam, 201S
midazolam, 1S
Sustained release tablets, 71

Tendamistate, 145
Terbutaline sulphate, 224P
Tetracyclines, 127
Theophylline
BCG, 735
disposition
diurnal changes, 413
oral contraceptives, 271
smoking, 271
elimination, 735
infusion, 405
maintenance dosage, 511
serum concentrations, 267
Therapeutic effect, 491
Therapy, 561
THIP, 477
Thromboxane A_2, 191
Timolol, 609
Tolbutamide, 438
Tolerance, 645
Trazodone
elderly subjects, 371
sleep, 139
Triazolam
effect comparison, 63S
efficacy, 407S
pharmacokinetics, 291S
out-patients, 179S
oxidation, 743
sleep-wakefulness, 29S
Tricyclic antidepressants, 651
Tryptophan, 215P
Tyramine pressor test, 427

Ulcerative colitis
colonic release, 185
jejunal instillation, 738
Uraemia, 221P
Urine pH
mexiletine, 281
phenoperidine, 101

Valproic acid
acute oral dosing, 225P, 365
pharmacokinetics, 104
Valsalva's manoeuvre, 9
Vascular responses, 209P
Vasodilation, 319
Vasodilator, 336
Vecuronium, 218P
Verapamil, 206P
Vesparax
insomnia, 161S
sleep disorders, 167S
Vitamin K_1, 683

Warfarin, 669

Xipamide, 208P

Young subjects, 104

Zopiclone
cf. diazepam, 216P
chronic liver disease, 259

British Journal of Clinical Pharmacology

NUMBER 1 JULY 1983

EDITORIALS

1 RICHENS, A. Standard units for expressing drug concentrations in biological fluids
3 STEWART, M.J. & WATSON, I.D. Standard units for expressing drug concentrations in biological fluids

PAPERS

9 BELLAMY, G.R., HUNYOR, S.N., ROFFE, D. & MASSANG, J. Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment
17 ISHIZAKI, T., OYAMA, Y., SUGANUMA, T., SASAKI, T., NAKAYA, H., SHIBUYA, T. & SATO, T. A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, β-adrenoceptor blockade and steady-state pharmacokinetics
27 MEREDITH, P.A., ELLIOTT, H.L., McSHARRY, D.R., KELMAN, A.W. & REID, J.L. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects
33 JÜRGENSEN, H.J., WIMBERLEY, P.D. & BRODTHAGEN, U. Oxyhaemoglobin equilibrium and chronic β-adrenoceptor blockade in coronary heart disease
39 HOFFMANN, J.J.M.L., THIEN, Th. & VAN T'LAAR, A. Effects of intravenous endralazine in essential hypertension
45 WATHEN, C.G., HANNAN, W.J., ADIE, C.J. & MUIR, A.L. A radionuclide method for the simultaneous study of the effects of drugs on central and peripheral haemodynamics
51 SERRUYS, P.W., VANHALEWEYK, G., VAN DEN BRAND, M., VERDOUW, P., LUBSEN, J. & HUGENHOLTZ, P.G. The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease
61 JUMA, F. & OGADA, T. Pharmacokinetics of cyclophosphamide in Kenyan africans
65 ADVENIER, C., ROUX, A., GOBERT, C., MASSIAS, P., VAROQUAUX, O. & FLOUVAT, B. Pharmacokinetics of ketoprofen in the elderly
71 LIEN, E. & BAKKE, O.M. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion
77 RENWICK, A.G., HIGGINS, V., POWERS, K., SMITH, C.L. & GEORGE, C.F. The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment
85 SÄWE, J., SVENSSON, J.O. & RANE, A. Morphine metabolism in cancer patients on increasing oral doses—no evidence for autoinduction or dose dependence
95 OBLOWITZ, H. & ROBINS, A.H. The effect of clobazam and lorazepam on the psychomotor performance of anxious patients

SHORT REPORTS

101 MILNE, L.A., WILLIAMS, N.E., CALVEY, T.N., MURRAY, G.R. & CHAN, K. Effect of urine pH on the elimination of phenoperidine
104 BRYSON, S.M., VERMA, N., SCOTT, P.J.W. & RUBIN, P.C., Pharmacokinetics of valproic acid in young and elderly subjects
106 CHING, M.S., RAYMOND, K., BURY, R.W., MASHFORD, M.L. & MORGAN, D.J. Absorption of orally administered amphotericin B lozenges
109 JOGESTRAND, T. & ERICSSON, F. Skeletal muscle digoxin binding in patients with renal failure
112 CALDARA, R., MASCI, E., BARBIERI, C., CAMBIELLI, M., FERRARI, C. & TITTOBELLO, A. Dopaminergic control of gastric acid and gastrin secretion in man: lack of effects after acute oral administration of ibopamine, an analogue of dopamine

LETTERS TO THE EDITORS

115 WILLIAMS, J. Standardization of units of drug concentration measurement
115 SCHNIEDEN, H. Open Letter to the Editors, British Journal of Clinical Pharmacology

NUMBER 2 AUGUST 1983

PAPERS

page

117 DUNK, A.A., JENKINS, W.J., BURROUGHS, A.K., WALT, R.P., OSUAFOR, T.O.K., SHERLOCK, S., MACKIE, S. & DICK, R. The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease

121 HEDNER, T., PERSSON, B. & BERGLUND, G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension

127 POTTS, R.C., MacCONNACHIE, A., BROWN, R.A., GIBBS, J.H., ROBERTSON, A.J., HASSAN, H.A.A. & SWANSON BECK, J. Some tetracycline drugs suppress mitogen-stimulated lymphocyte growth but others do not

133 RAPEPORT, W.G., McINNES, G.T., THOMPSON, G.G., FORREST, G., PARK, B.K. & BRODIE, M.J. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine

139 MONTGOMERY, I., OSWALD, I., MORGAN, K. & ADAM, KIRSTINE Trazodone enhances sleep in subjective quality but not in objective duration

145 MEYER, B.H., MÜLLER, F.O., CLUR, B.K. & GRIGOLEIT, H.-G. Effects of tendamistate (α-amylase inactivator) on starch metabolism

149 STACHER, G., STEINRINGER, H., WINKLEHNER, S., MITTELBACH, G. & SCHNEIDER, C. Effects of graded oral doses of meptazinol and pentazocine in comparison with placebo on experimentally induced pain in healthy humans

157 DEVONSHIRE, H.W., KONG, I., COOPER, M., SLOAN, T.P., IDLE, J.R. & SMITH, R.L. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition

167 ARNOLD, J.M.O. & McDEVITT, D.G. An assessment of physiological finger tremor as an indicator of β-adrenoceptor function

175 ARNOLD, J.M.O. & McDEVITT, D.G. Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine

SHORT REPORTS

185 DEW, M.J., RYDER, R.E.J., EVANS, N., EVANS, B.K. & RHODES, J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis

188 JACK, D.B., WILKINS, M. & QUARTERMAN, C.P. Lack of evidence for polymorphism in metoprolol metabolism

191 LEVY, MICHA, ELDOR, AMIRAM, ZYLBER-KATZ, ESTER & ELIAKIM, M. The effects of long-term colchicine therapy in patients with recurrent polyserositis on the capacity of blood platelets to synthesise thromboxane A_2

195 FEELY, J., CLEE, M., PEREIRA, LORETTA & GUY, ELIZABETH Enzyme induction with rifampicin: lipoproteins and drug binding to α_1-acid glycoprotein

LETTERS TO THE EDITORS

199 LAURIKAINEN, E. & KANTO, J. Saliva concentrations of lignocaine in patients with acute myocardial ischaemia

200 ANKIER, S.I., BARCLAY, S.P. & WARRINGTON, S.J. Loprazolam (RU31158)—lack of effect on hepatic microsomal enzyme activity in man

201 ALTAMURA, A.C. & MELORIO, T. Mianserin metabolites

202 PINDER, R.M. Mianserin pharmacokinetics—a reply

PROCEEDINGS

205 Proceedings of the British Pharmacological Society (University of Cambridge, 6–8 April 1983)

NUMBER 3 SEPTEMBER 1983

PAPERS

page

233 PIKE, EVA, KIERULF, P., SKUTERUD, B., BREDESEN, J.E. & LUNDE, P.K.M. Drug binding in sera deficient in lipoproteins, albumin or orosomucoid

241 BATEMAN, D.N., CHAPMAN, P.H. & RAWLINS, M.D. The acute and chronic effects of H_1 receptor blockade with astemizole on indocyanine green clearance

245 HOUIN, G., BRUNNER, F., NEBOUT, Th., CHERFAOUI, M., LAGRUE, G. & TILLEMENT, J.P. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man

253 SMITH, R.S., WARREN, D.J., RENWICK, A.G. & GEORGE, C.F. Acebutolol pharmacokinetics in renal failure

259 PARKER, GLYNIS & ROBERTS, C.J.C. Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease

267 THOMPSON, P.J., SKYPALA, I., DAWSON, S., McALLISTER, W.A.C. & TURNER WARWICK, M. The effect of diet upon serum concentrations of theophylline

271 GARDNER, M.J., TORNATORE, K.M., JUSKO, W.J. & KANARKOWSKI, R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition

281 MITCHELL, B.G., CLEMENTS, J.A., POTTAGE, A. & PRESCOTT, L.F. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation

285 MILLIGAN, N., OXLEY, J. & RICHENS, A. Acute effects of intravenous phenytoin on the frequency of inter-ictal spikes in man

291 McMANUS, I.C., ANKIER, S.I., NORFOLK, J., PHILLIPS, M. & PRIEST, R.G. Effects on psychological performance of the benzodiazepine, loprazolam, alone and with alcohol

301 LAPORTE, JOAN-RAMON, PORTA, M. & CAPELLA, DOLORS Drug utilization studies: a tool for determining the effectiveness of drug use

305 ZOCCALI, C., ZABLUDOWSKI, J.R., ISLES, C.G., MURRAY, G.D., INGLIS, G.C., ROBERTSON, J.I.S., FRASER, R. & BALL, S.G. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man

313 RENARD, M., JACOBS, Ph., MOLS, P., MELOT, Ch., DRESSE, A. & BERNARD, R. The effective plasma concentrations of sulmazol (AR-L 115 BS) on haemodynamics in chronic heart failure

319 HENDRIKS, F.F.A. & SCHIPPERHEYN, J.J. Transients in oxygen uptake after step-increase of workload under β-adrenoceptor blockade or vasodilation

327 ROBINSON, B.F., DOBBS, R.J. & PHILLIPS, R.J.W. Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension

SHORT REPORTS

333 MASON, G., RAWLINS, M.D. & SHUSTER, S. Blood monocyte aryl hydrocarbon hydroxylase activity in psoriasis

336 RAMSAY, L.E. & FREESTONE, S. Preliminary evaluation of pinacidil in hypertension

LETTERS TO THE EDITORS

339 ZAR, M.A. & GOOPTU, D. Effect of nifedipine on the contractile responses of human colonic muscle

340 TAYLOR, W.B. & BATEMAN, D.N. High dose metoclopramide—preliminary pharmacokinetic studies

342 STRUTHERS, A.D. & REID, J.L. Nifedipine does not influence adrenaline induced hypokalaemia in man

344 HOLT, D.W., HAYLER, A.M. & HEALEY, G.F. Effect of age and plasma concentrations of albumin and α_1-acid glycoprotein on protein binding of disopyramide

345 PIERCE, D.M. & FRANKLIN, R.A. The classification of benzodiazepine hypnotics

349 OBITUARY
351 THE LATE PROFESSOR J. CROOKS, C.B.E. *1982 Lilly Prize Lecture* Drug epidemiology and clinical pharmacology: their contribution to patient care

PAPERS

359 LENNARD, L., REES, C.A., LILLEYMAN, J.S. & MADDOCKS, J.L. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia
365 RAPEPORT, W.G., MENDELOW, A.D., FRENCH, G., MacPHERSON, P., TEASDALE, E., AGNEW, E., THOMPSON, G.G. & BRODIE, M.J. Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing
371 BAYER, A.J., PATHY, M.S.J. & ANKIER, S.I. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly
377 DÜSING, R., NICOLAS, V., GLATTE, BIRGIT, GLÄNZER, K., KIPNOWSKI, J. & KRAMER, H.J. Interaction of bemetizide and indomethacin in the kidney
385 ARMSTRONG, P.W., WATTS, D.G. & MOFFAT, J.A. Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure
391 ANDREASEN, F., HANSEN, U., HUSTED, S.E. & JANSEN, J.A. The pharmacokinetics of frusemide are influenced by age
399 WHITE, N.J., CHANTHAVANICH, P., KRISHNA, S., BUNCH, C. & SILAMUT, K. Quinine disposition kinetics
405 WARREN, J.B., TURNER, C., DALTON, N., THOMSON, A., COCHRANE, G.M. & CLARK, T.J.H. The effect of posture on the sympathoadrenal response to theophylline infusion
413 TAYLOR, D.R., DUFFIN, D., KINNEY, C.D. & McDEVITT, D.G. Investigation of diurnal changes in the disposition of theophylline
417 O'CALLAGHAN, W.G., LAHER, M.S., McGARRY, K., O'BRIEN, E. & O'MALLEY, K. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients
423 SOWEMIMO-COKER, S.O., KOVACS., IREN B., PICKLES, HILARY, HEDGES, ANNMARIE & TURNER, P. Dipyridamole increases red cell deformability

SHORT REPORTS

427 JACKSON, S.H.D., TURNER, P. & EHSANULLAH, R.S.B. A comparison of diclofensine and desmethylimipramine using tyramine pressor tests in normal subjects
430 WANG, C., WONG, K.L., LAM, K.C. & LAI, C.L. Ranitidine does not affect gonadal function in man
433 WOOLF, A.D., ROGERS, H.J., BRADBROOK, I.D. & CORLESS, D. Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients
438 DEY, N.G., CASTLEDEN, C.M., WARD, J., CORNHILL, J. & McBURNEY, A. The effect of cimetidine on tolbutamide kinetics
441 SCOTT, A.K., KHIR, A.S.M., STEELE, W.H., HAWKSWORTH, G.M. & PETRIE, J.C. Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone
445 GIBB, I., ADAMS, P.C., PARNHAM, A.J. & JENNINGS, K. Plasma digoxin: assay anomalies in Fab-treated patients
448 GLEESON, D., ROSE, J.D.R. & SMITH, P.M. A prospective randomised controlled trial of diazepam (Valium) *vs* emulsified diazepam (Diazemuls) as a premedication for upper gastrointestinal endoscopy
451 HARRON, D.W.G., ARNDTS, D., FINCH, M. & SHANKS, R.G. An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine
456 CHANNER, K.S., BOLTON, R., AL-HILLI, S., NAKIELNY, R. & VIRJEE, J.P. The effect of glucagon on the swallowing of capsules

LETTERS TO THE EDITORS

459 BARRADAS, M.A., MIKHAILIDIS, D.P. & DANDONA, P. The effect of fenfluramine on collagen-induced platelet aggregation *in vitro*

460 BACK, D.J., PARK, B.K., TIJA, J.F. & NEWBY, S.N. Sulphaphenazole and drug oxidation in man
461 DAMMANN, H.G., FRIEDL, W., MÜLLER, P. & SIMON, B. Effect of ranitidine and cimetidine twice daily on the 24 h intragastric acidity in man

NUMBER 5 NOVEMBER 1983

PAPERS

465 GILCHRIST, N., BOLTON, JENNIFER, E., DONALD, R.A., LIVESEY, J.H., ROUD, HELEN K. & NICHOLLS, M.G. Hormonal effects and metabolic clearance rate of the enkephalin analogue DAMME in man
461 QUATTRONE, A., TEDESCHI, G., AGUGLIA, U., SCOPACASA, F., DIRENZO, G.F. & ANNUNZIATO, L. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine
477 KJAER, M. & NIELSEN, H. The analgesic effect of the GABA-agonist THIP in patients with chronic pain of malignant origin. A phase-1-2 study
487 HONG, C.Y., CHIANG, B.N. & WEI, Y.H. Mitochondrial respiration inhibitors and human sperm motility: implication in the development of spermicides
491 THIJSSEN, H.H.W. & BAARS, L.G. Active metabolites of acenocoumarol: do they contribute to the therapeutic effect?
497 BACK, D.J., PURBA, H.S., PARK, B.K., WARD, S.A. & ORME, M.L'E. Effect of chloroquine and primaquine on antipyrine metabolism
503 MINERS, J.O., ATTWOOD, J. & BIRKETT, D.J. Influence of sex and oral contraceptive steroids on paracetamol metabolism
511 TAYLOR, D.R., KINNEY, C.D. & McDEVITT, D.G. Prediction of maintenance oral theophylline dosage using single oral doses in patients with obstructive airways disease
517 VAIDYA, ASHOK B., RAY, D.K., MANKODI, N.A., PAUL, TERESA & SHETH, U.K. Phase 1 tolerability and antiamoebic activity studies with 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone (Go. 10213): a new antiprotozoal agent
523 PREISS, D. & BERGUSON, P. Dose-response studies on glycopyrrolate and atropine in conscious cardiac patients
529 SILKE, B., VERMA, S.P., HUSSAIN, M., NELSON, G.I.C., OKOLI, R.C. & TAYLOR, S.H. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris
537 VANDENBURG, M.J., SHARMAN, V.L., WRIGHT, PAT, DREW, P.J. & BARNES, J.N. Hydralazine and prazosin in the treatment of hypertension
543 RUBIN, P.C., BUTTERS, LUCY, LOW, R.A. & REID, J.L. Clinical pharmacological studies with prazosin during pregnancy complicated with hypertension

SHORT REPORTS

549 KAMPMANN, J.P. & MOLHOLM HANSEN, J.E. Serum binding of propylthiouracil
553 STAESSEN, J., CATTAERT, A., de SCHAEPDRYVER, A., FAGARD, R., LIJNEN, P., MOERMAN, E. & AMERY, A. Effects of β_1-adrenoceptor agonism on plasma renin activity in normal men
557 ROLF SMITH, S., KENDALL, M.J., WORTHINGTON, D.J. & HOLDER, R. Can the biochemical responses to a β_1-adrenoceptor stimulant be used to assess the selectivity of β_2-adrenoceptor blockers?
561 CHADHA, D.R. & HOUTZAGERS, J.J.R. A comparison of a combination of penbutolol and frusemide with the two compounds individually in the treatment of hypertension
565 HERMAN, R.J., NAKAMURA, K., WILKINSON, G.R. & WOOD, A.J.J. Induction of propranolol metabolism by rifampicin
570 COOPER, M.J. & WILLIAMSON, R.C.N. The action of salicylates on bile flow in man

LETTERS TO THE EDITORS

573 GUNDERT-REMY, URSULA & HILDEBRANDT, RUTH Binding of theophylline and its metabolites to human plasma proteins
574 LYALL, M.G., BAINBRIDGE, J.G. & KHAMBATTA, R.B. Opthalmological monitoring of patients receiving long-term acebutolol

576 ALI, H.M., HOMEIDA, M.M.A. & EL-ZEIN, I. Effect of ethnic origin on ampicillin bioavailability in healthy Sudanese subjects
578 BOSTON, P.F. Paracetamol absorption from Paramax, Panadol and Solpadeine
579 NEWMAN, G.B. Statistical analysis of data on paracetamol absorption

NUMBER 6 DECEMBER 1983

PERSONAL VIEW

581 CASTLE, WINIFRED, M., NICHOLLS, J.T. & DOWNIE, C.C. Problems of postmarketing surveillance

PAPERS

587 TATTERSFIELD, A.E. & CRAGG, D.J. Effect of ICI 118551 on bronchial β-adrenoceptor function and exercise heart rate in normal man
591 EDMONDSTONE, W.M., WALLER, J.F., MANGHANI, K.K., HILL, P.L., BELL, A.J. & DENISON, D.M. Pulmonary effects in man of oral prizidilol hydrochloride (SK&F 92657), a new antihypertensive agent
599 HURWITZ, G.A., WEBB, J.G., WALLE, T., BAI, S.A., DANIELL, H.B., GOURLEY, L., BOYD LOADHOLT, C. & GAFFNEY, T.E. Exercise-induced increments in plasma levels of propranolol and noradrenaline
609 GRIFFITHS, B.E., CREAGH, FIONUALA, M., LAZARUS, J.H., JOHN, R. & KADURY, SANA Effect of timolol on clinical features and endocardiographic assessment of left ventricular function in hyperthyroidism
615 STANIFORTH, D.H. The QT interval and cycle length: the influence of atropine, hyoscine and exercise
623 GRAINGER, S.L. & SMITH, S.E. Dose-response relationships of intravenous hyoscine butylbromide and atropine sulphate on heart rate in healthy volunteers
627 HILAIRE, J., BROUSTET, J.P., COLLE, J.P. & THERON, M. Cardiovascular effects of AQ-A 39 in healthy volunteers
633 DIFFEY, B.L. & BROWN, S. A method for predicting the phototoxicity of non-steroidal anti-inflammatory drugs
639 COLLIER, J.G. & FULLER, R.W. Evidence for an effect of sodium cromoglycate on sensory nerves in man
645 FILE, SANDRA E. & LISTER, R.G. Does tolerance to lorazepam develop with once weekly dosing?
651 CRESTEIL, T., CÉLIER, C., KREMERS, P., FLINOIS, J.P., BEAUNE, Ph. & LEROUX, L.P. Induction of drug-metabolizing enzymes by tricyclic antidepressants in human liver: characterization and partial resolution of cytochrome P-450
659 RUBIN, P.C., BUTTERS, LUCY, REYNOLDS, B., EVANS, J., SUMNER, D., LOW, R.A. & REID, J.L. Atenolol elimination in the neonate
663 MARKEL, A., BROOK, J.G., LEVY, Y., AVIRAM, M. & YOUDIM, M.B.H. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol
669 BANFIELD, C., O'REILLY, R., CHAN, ELI & ROWLAND, M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations
677 McGOWAN, F.X., NASH, PATRICIA V. & BJORNSSON, T.D. Assay-dependent kinetics of heparin: evidence for rapid *in vivo* activation of heparin
683 BECHTOLD, H., TRENK, D., MEINERTZ, T., ROWLAND, M. & JAHNCHEN, E. Cyclic interconversion of vitamin K_1 and vitamin $K_1$2,3-epoxide in man
691 BREIBY, M., AARBAKKE, J., SUNDSFJORD, J., COUSSIUS, G. & PAPE, J. Effect of posture on ampicillin pharmacokinetics, glomerular filtration rate and renal plasma flow in resting subjects
695 IBRAHEEM, J.J., PAALZOW, L. & TFELT-HANSEN, P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers
701 WALKER, OLADAPO, DAWODU, A.H., ADEYOKUNNU, A.A., SALAKO, L.A. & ALVAN, G. Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria

SHORT REPORTS

707 COOK, P.J., MAIDMENT, C.G., DANDONA, P., HUTTON, R.A. & JAMES, I.M. The effect of intravenous epoprostenol (prostacyclin, PGI_2) on cerebral blood flow and cardiac output in man

712 ETIENNE, JACQUELINE, MILLOT, FRANCOISE, PIERON, RENE & LARUELLE, P. Release of LPL activity after intravenous injection of a low molecular weight heparin

715 BARR, R.M., MISCH, K.J., HENSBY, C.N., MALLET, A.I. & GREAVES, M.W. Arachidonic acid and prostaglandin levels in dithranol erythema: time course study

718 ARMISTEAD, J.G., LIGHTMAN, S.L., BROWN, I.J., CAUSON, R.C. & VAUGHAN, N.J.A. The effect of selective and non-selective β-adrenoceptor blockade, and of naloxone infusion, on the hormonal mechanisms of recovery from insulin-induced hypoglycaemia in man

722 SINGH, H., RIMMER, A., LEWIS, M.J. & HENDERSON, A.H. β-adrenoceptor hypersensensitivity after stopping oxprenolol: discrepant findings not attributable to methodology

725 HUYSMANS, F.Th.M., SLUITER, H.E., THIEN, Th.A. & KOENE, R.A.P. Acute treatment of hypertensive crisis with nifedipine

728 CENRAUD, B., GUYOT, M., LEVY, R.H., BRACHET-LIERMAIN, A., MORSELLI, P.L., MORELAND, T.A. & LOISEAU, P. No effect of food intake on clobazam absorption

731 MEFFIN, P.J., GRGURINOVICH, N., BROOKS, P.M., MINERS, J.O., COCHRAN, M. & STRANKS, G. Ranitidine disposition in patients with renal impairment

735 GRAY, JEAN D., RENTON, K.W. & HUNG, O.R. Depression of theophylline elimination following BCG vaccination

738 HAAGEN NIELSEN, O. & BONDESEN, S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man

741 MAGNUSSON, J.O. Metabolism of digoxin after oral and intrajejunal administration

743 OCHS, H.R. & GREENBLATT, D.J. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation

747 BRODIE, M.J., FORREST, G. & RAPEPORT, W.G. Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants

751 BENEDEK, I.H., FISKE, W.D., GRIFFEN, W.O., BELL, R.M., BLOUIN, R.A. & McNAMARA, P.J. Serum α_1-acid glycoprotein and the binding of drugs in obesity

LETTERS TO THE EDITORS

755 COLUSSI, D., SCHOELLER, J.P., RICHARD, A. & SIOUFI, A. Pharmacokinetics of chlorthalidone in the elderly after single and multiple doses

756 MINESHITA, S. Influence of gastrectomy on aspirin absorption

758 MOSES, D.K., CHARLES, B.G., RAVENSCROFT, P.J. & WHYTE, I.M. Food reduces the oral bioavailability of propantheline bromide in healthy subjects

759 BATEMAN, D.N. & RAWLINS, M.D. The effects of astemizole on antipyrine clearance

760 PLYM FORSHELL, G., GUNNARSSON, P.O. & LILJEKVIST, J. On the clinical pharmacology of prednimustine

762 NEWELL, D.R., CALVERT, A.H., HARRAP, K.R. & McELWAIN, T.J. The clinical pharmacology of chlorambucil and prednimustine

INDEXES

765 Author and Subject Indexes for Volume 16

VOLUME 16 SUPPLEMENT 1 1983

EDITORIAL

1S NICHOLSON, A.N. Foreword

CHEMISTRY, PHARMACOLOGY, TOXICOLOGY AND PHARMACOKINETICS

5S AMREIN, R., ECKERT, M., HAEFELI, H. & LEISHMAN, B. Pharmacokinetic and clinical considerations in the choice of a hypnotic

11S GERECKE, M. Chemical structure and properties of midazolam compared with other benzodiazepines
17S PIERI, L. Preclinical pharmacology of midazolam
29S SCHERSCHLICHT, R. & MARIAS, J. Effects of oral and intravenous midazolam, triazolam and flunitrazepam on the sleep–wakefulness cycle of rabbits.
37S SCHLÄPPI, B. Safety aspects of midazolam
43S HEIZMANN, P., ECKERT, M. & ZIEGLER, W.H. Pharmacokinetics and bioavailability of midazolam in man
51S CREVOISIER, Ch., ZIEGLER, W.H., ECKERT, M. & HEIZMANN, P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration
63S ZIEGLER, W.H., SCHALCH, E., LEISHMAN, B. & ECKERT, M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites

SLEEP LABORATORY AND PERFORMANCE STUDIES

73S SCOLLO-LAVIZZARI, G. Hypnotic efficacy and clinical safety of midazolam in shift-workers
79S KRIEGER, J., MANGIN, P. & KURTZ, D. Effects of midazolam on sleep in normal subjects
81S ZIEGLER, G., LUDWIG, L. & KLOTZ, U. Effect of midazolam on sleep
87S MONTI, J.M., DEBELLIS, J., ALTERWAIN, P. & D'ANGELO, L. Midazolam and sleep in insomniac patients
89S GATH, I., BAR-ON, E., ROGOWSKI, Z. & BENTAL, E. Automatic scoring of polygraphic sleep recordings: Midazolam in insomniacs
97S POPOVICIU, L. & CORFARIU, O. Efficacy and safety of midazolam in the treatment of night terrors in children
103S VOGEL, G.W. & VOGEL, F. Effect of midazolam on sleep of insomniacs
109S HAURI, P., ROTH, T., SATEIA, M. & ZORICK, F. Sleep laboratory and performance evaluation of midazolam in insomniacs
115S NICHOLSON, A.N. & STONE, BARBARA M. Midazolam: Sleep and performance studies in middle age
121S GUDGEON, A.C. & HINDMARCH, I. Midazolam: Effects on psychomotor performance and subjective aspects of sleep and sedation in normal volunteers

CLINICAL STUDIES IN INSOMNIA

129S DU CAILAR, J., HOLZER, J., JULLIEN, Y. & PASSERON, D. Hypnotic efficacy of midazolam in pre-surgical patients: a dose-finding study
133S BECK, H., SALOM, M. & HOLZER, J. Midazolam dosage studies in institutionalized geriatric patients
139S LUPOLOVER, R., BALLMER, U., HELCL, J., ESCHER, J. & PAVLETIC, B. Efficacy and safety of midazolam and oxazepam in insomniacs
145S GALLAIS, H., CASANOVA, P. & FABREGAT, H. Midazolam and oxazepam in the treatment of insomnia in hospitalized patients
151S FELDMEIER, Ch. & KAPP, W. Comparative clinical studies with midazolam, oxazepam and placebo
157S FISCHBACH, R. Hypnotic efficacy and safety of midazolam and oxazepam in hospitalized female patients
161S PHILIPP, E. & KAPP, W. Comparative study of midazolam and Vesparax in moderate or severe insomnia in female surgical patients
167S FISCHBACH, R. Efficacy and safety of midazolam and Vesparax in treatment of sleep disorders
173S LACHNIT, K.S., PROSZOWSKI, E. & RIEDER, L. Midazolam in the treatment of sleep disorders in geriatric patients
179S COSTA E SILVA, J.A., ACIOLI, A., NAYLOR, C., JONES DA SILVA, C. & FERREIRA, I. Midazolam and triazolam in out-patients: a double-blind comparison of hypnotic efficacy

APPLICATIONS IN ANAESTHESIA

187S GEMPERLE, M. & KAPP, W. Midazolam and anaesthesia

BIBLIOGRAPHY

191S Midazolam bibliography

VOLUME 16 SUPPLEMENT 2 1983

201S NICHOLSON, A.N. Foreword

INVITED LECTURES

205S GAILLARD, J.-M. Biochemical pharmacology of paradoxical sleep
231S DANNEBERG, P. & WEBER, K.H. Chemical structure and biological activity of the diazepines
245S COHN, M.A. Hypnotics and the control of breathing

ANIMAL STUDIES

253S KUHN, F.J., BÖKE-KUHN, KARIN, DANNEBERG, P., LEHR, E. & STOCKHAUS, K. Pharmacology and hypnogenic properties of brotizolam in animals
261S BECHTEL, W.D. Pharmacokinetics and metabolism of brotizolam in animals
267S HEWETT, C., KREUZER, H., KÖLLMER, H., NIGGESCHULZE, A. & STÖTZER, H. Toxicology of brotizolam

CLINICAL PHARMACOKINETICS

277S BREIMER, D.D. & JOCHEMSEN, ROELINE Clinical pharmacology of hypnotic benzodiazepines: a summary
279S BECHTEL, W.D. Pharmacokinetics and metabolism of brotizolam in humans
285S JOCHEMSEN, ROELINE, WESSELMAN, J.G.J., HERMANS, J., van BOXTEL, C.J. & BREIMER, D.D. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration
291S JOCHEMSEN, ROELINE, WESSELMAN, J.G.J., HERMANS, J., van BOXTEL, C.J. & BREIMER, D.D. Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects
299S JOCHEMSEN, ROELINE, NANDI, K.L., CORLESS, D., WESSELMAN, J.G.J. & BREIMER, D.D. Pharmacokinetics of brotizolam in the elderly
309S EVERS, J., RENNER, E. & BECHTEL, W.D. Pharmacokinetics of brotizolam in renal failure
315S JOCHEMSEN, ROELINE, JOERES, R.P., WESSELMAN, J.G.J., RICHTER, E. & BREIMER, D.D. Pharmacokinetics of oral brotizolam in patients with liver cirrhosis

PHARMACODYNAMICS AND PERFORMANCE

325S TANAKA, M., ISOZAKI, H., MIZUKI, Y. & INANAGA, K. Effect of brotizolam on the averaged photopalpebral reflex in man
333S SALETU, B., GRÜNEBERGER, J. & LINZMAYER, L. Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers
347S KRUEGER, H. & MÜLLER-LIMMROTH, W. Residual effects of flurazepam and brotizolam on psychomotor performance

SLEEP LABORATORY STUDIES

355S HARTSE, K.M., THORNBY, J.I., KARACAN, I. & WILLIAMS, R.L. Effects of brotizolam, flurazepam and placebo upon nocturnal auditory arousal thresholds

365S NICHOLSON, A.N. Brotizolam: studies of effects on sleep and on performance in young adulthood and in middle age
371S ROEHRS, T., ZORICK, F., KOSHOREK, G.L., WITTIG, R. & ROTH, T. Effect of acute administration of brotizolam in subjects with disturbed sleep
377S MAMELAK, M., CSIMA, ADELE & PRICE, VICTORIA Effects of brotizolam on the sleep of chronic insomniacs

CLINICAL STUDIES

385S VON DELBRÜCK, ORLA, GOETZKE, EDDA & NAGEL, CORNELIA Tolerance studies with brotizolam in hospitalized patients
391S VON DELBRÜCK, ORLA, GOETZKE, EDDA & LICHTERFELD, A. Efficacy and acceptability of brotizolam in the elderly
397S GOETZKE, EDDA, FINDEISEN, P. & WELBERS, INÉS B. Tolerance and efficacy: comparative studies with brotizolam and flunitrazepam
403S LOHMANN, H., VON DELBRÜCK, ORLA & FINDEISEN, P. Comparative studies on the efficacy of brotizolam and nitrazepam: a multi-centre study
407S GOETZKE, EDDA, FINDEISEN, P. & WELBERS, INÉS, B. Comparative study on the efficacy of and the tolerance to the triazolodiazepines, triazolam and brotizolam
413S FRITZ-OSNER, A. ARIAS-ORTIZ, J.L., DORANTES, J.F., RABAGO-SÁNCHEZ, J., RODRÍGUEZ-TENORIO, A. & SÁNCHEZ-MARTINEZ, J. Brotizolam and chronic insomnia: a multi-centre study
415S WHEATLEY, D. Studies in general practice with brotizolam
417S UZZAN, B., WAROT, D., CHERMAT, P., DANTLO, B., BORNSTEIN, S. & SIMON, P. Hypnotic activity of brotizolam: a study in general practice
419S AHMAD, F., RITTMEYER, P., GOETZKE, EDDA & KÖSTER, J. Brotizolam as a pre-operative hypnotic
425S SYBRECHT, G.W. Influence of brotizolam on the ventilatory and mouth-occlusion pressure response to hypercapnia in patients with chronic obstructive pulmonary disease

REVIEW OF CLINICAL STUDIES

433S NICHOLSON, A.N. Brotizolam: review of clinical studies